Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment

array:23 ["pii" => "S0301054616300763" "issn" => "03010546" "doi" => "10.1016/j.aller.2016.04.014" "estado" => "S300" "fechaPublicacion" => "2017-01-01" "aid" => "774" "copyright" => "SEICAP" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Allergol Immunopathol (Madr). 2017;45:55-62" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 30 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 11 "PDF" => 11 ] ] "itemSiguiente" => array:18 [ "pii" => "S0301054616301057" "issn" => "03010546" "doi" => "10.1016/j.aller.2016.06.005" "estado" => "S300" "fechaPublicacion" => "2017-01-01" "aid" => "789" "copyright" => "SEICAP" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Allergol Immunopathol (Madr). 2017;45:63-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 24 "formatos" => array:3 [ "EPUB" => 3 "HTML" => 11 "PDF" => 10 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "Efficacy of parthenolide on lung histopathology in a murine model of asthma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "63" "paginaFinal" => "68" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2148 "Ancho" => 3295 "Tamanyo" => 1413667 ] ] "descripcion" => array:1 [ "en" => "Light and electron microscopic findings of study groups. I; control (n:7), II; placebo (n:7), III; dexamethasone (n:7), IV; parthenolide (n:7), V; parthenolide and dexamethasone (n:7), A; H&E, B; PAS, C; Toluidine staining. (A) Arrow with two heads; sub-epithelial smooth muscle thickening, * peribronchial mononuclear cell infiltration. (B) arrows; goblet cells (C) arrows; mast cells. (D) Electron microscopic views. Increased goblet cells in placebo group (Gc), smooth muscle thickening (Sm)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Z. Arıkan-Ayyıldız, M. Karaman, S. Özbal, A. Bağrıyanık, O. Yilmaz, Ö. Karaman, N. Uzuner" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Z." "apellidos" => "Arıkan-Ayyıldız" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Karaman" ] 2 => array:2 [ "nombre" => "S." "apellidos" => "Özbal" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Bağrıyanık" ] 4 => array:2 [ "nombre" => "O." "apellidos" => "Yilmaz" ] 5 => array:2 [ "nombre" => "Ö." "apellidos" => "Karaman" ] 6 => array:2 [ "nombre" => "N." "apellidos" => "Uzuner" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0301054616301057?idApp=UINPBA00004N" "url" => "/03010546/0000004500000001/v1_201612300037/S0301054616301057/v1_201612300037/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0301054616300970" "issn" => "03010546" "doi" => "10.1016/j.aller.2016.06.004" "estado" => "S300" "fechaPublicacion" => "2017-01-01" "aid" => "784" "copyright" => "SEICAP" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Allergol Immunopathol (Madr). 2017;45:48-54" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 40 "formatos" => array:2 [ "HTML" => 31 "PDF" => 9 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "Food allergy in Catalonia: Clinical manifestations and its association with airborne allergens" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "48" "paginaFinal" => "54" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 2191 "Ancho" => 1571 "Tamanyo" => 173317 ] ] "descripcion" => array:1 [ "en" => "Clinical manifestations of the main food/food groups elicitors of allergic reactions. GIS: Gastrointestinal symptoms; OAS: oral allergy syndrome." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Sánchez-López, V. Gázquez, N. Rubira, L. Valdesoiro, M. Guilarte, A. Garcia-Moral, N. Depreux, L. Soto-Retes, M. De Molina, O. Luengo, R. Lleonart, M. Basagaña" "autores" => array:12 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Sánchez-López" ] 1 => array:2 [ "nombre" => "V." "apellidos" => "Gázquez" ] 2 => array:2 [ "nombre" => "N." "apellidos" => "Rubira" ] 3 => array:2 [ "nombre" => "L." "apellidos" => "Valdesoiro" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Guilarte" ] 5 => array:2 [ "nombre" => "A." "apellidos" => "Garcia-Moral" ] 6 => array:2 [ "nombre" => "N." "apellidos" => "Depreux" ] 7 => array:2 [ "nombre" => "L." "apellidos" => "Soto-Retes" ] 8 => array:2 [ "nombre" => "M." "apellidos" => "De Molina" ] 9 => array:2 [ "nombre" => "O." "apellidos" => "Luengo" ] 10 => array:2 [ "nombre" => "R." "apellidos" => "Lleonart" ] 11 => array:2 [ "nombre" => "M." "apellidos" => "Basagaña" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0301054616300970?idApp=UINPBA00004N" "url" => "/03010546/0000004500000001/v1_201612300037/S0301054616300970/v1_201612300037/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "55" "paginaFinal" => "62" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "R.M. Simão-Gurge, B.T. Costa-Carvalho, F.A. Nobre, I.G.S. Gonzalez, M.I. de Moraes-Pinto" "autores" => array:5 [ 0 => array:3 [ "nombre" => "R.M." "apellidos" => "Simão-Gurge" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "B.T." "apellidos" => "Costa-Carvalho" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "F.A." "apellidos" => "Nobre" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "I.G.S." "apellidos" => "Gonzalez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 4 => array:4 [ "nombre" => "M.I." "apellidos" => "de Moraes-Pinto" "email" => array:1 [ 0 => "m.isabelmp@uol.com.br" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Division of Pediatric Infectious Diseases, Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, SP, Brazil" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, SP, Brazil" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1455 "Ancho" => 3345 "Tamanyo" => 245452 ] ] "descripcion" => array:1 [ "en" => "Correlation between total IgG and pneumococcal antibodies of six serotypes of pneumococcal measured in 84 serum samples of patients on regular use of intravenous immunoglobulin." ] ] ] "textoCompleto" => "IntroductionThe main clinical features of patients with hypogammaglobinaemia are recurrent infections of the respiratory tract with Streptococcus pneumoniae being the most frequent isolated bacterium.<a class="elsevierStyleCrossRef" href="#bib0150">1</a> Long-term administration of immunoglobulin reduces the incidence of infection. However, some patients with common variable immunodeficiency (CVID) may continue to experience upper respiratory tract infections (URTIs) that lead to permanent lung damage, and the optimal trough level for serum IgG remains under discussion.<a class="elsevierStyleCrossRefs" href="#bib0155">2,3</a>The minimum concentration of serotype-specific S. pneumoniae antibodies considered to be protective is widely debated. The World Health Organization (W.H.O.) considers the concentration of 0.35μg/mL as protective for invasive pneumococcal disease in healthy children.<a class="elsevierStyleCrossRef" href="#bib0165">4</a> However, individuals with recurrent infections may require higher antibody levels such as 1.3μg/mL for protection.<a class="elsevierStyleCrossRef" href="#bib0170">5</a> Moreover, antibody concentrations required for the prevention of pneumonia, otitis media or colonisation have yet to be established.<a class="elsevierStyleCrossRefs" href="#bib0165">4,6</a>Over the past two decades, administration of exogenous pooled human immunoglobulin for intravenous use has become an important therapy in clinical medicine for patients with antibody deficiencies. Passive immunisation by intravenous immunoglobulin (IVIG) has been shown to reduce infections in these patients, especially those from encapsulated bacteria such as S. pneumoniae and Haemophilus influenzae type b (Hib).<a class="elsevierStyleCrossRefs" href="#bib0180">7,8</a> Antibodies to S. pneumoniae have been quantified in IVIG samples in a few studies, without concomitant serum antibody level assessment,<a class="elsevierStyleCrossRefs" href="#bib0190">9,10</a> and some were quantified in sera only.<a class="elsevierStyleCrossRefs" href="#bib0200">11,12</a> Therefore, monitoring antibody levels in these patients is necessary.The goal of this study was to evaluate serum antibody levels to S. pneumoniae in patients with impaired production of IgG antibodies in regular use of IVIG replacement and to correlate these levels to IVIG preparations as well as to infectious episodes in each patient during the study period.Patients and methodsThis is a prospective study approved by the Ethics Committee of the Federal University of São Paulo that is in accordance with the World Medical Association and the Helsinki Declaration. Twenty-one patients on regular IVIG replacement therapy were evaluated: 12 with CVID, six with X-linked agammaglobulinaemia (XLA) and three with hyper-IgM syndrome (HIM). Administration of IVIG was performed at intervals of 28 days (range, 21–34 days).At the beginning of the study, a questionnaire was filled in with the following data: date of birth, gender, diagnosis of immunodeficiency, age at diagnosis, period of treatment, dose of IVIG. During the study, episodes of infections and antibiotic administration were also recorded.Two of the three hyper-IgM patients had absence of pneumococcal antibodies after vaccine and the third had an early diagnosis and was not immunised. Out of the 12 CVID patients, eight had absence of antibodies to polysaccharide antigens and in four of them these antibodies were not tested but IgG levels were less than 0.4g/L at diagnosis. As XLA patients do not produce antibodies, they were not tested before IVIG replacement therapy initiation.Collection of blood and IVIG samplesAfter written informed consent and immediately before IVIG infusion, a 10mL blood sample was collected totalling 84 samples that were centrifuged at 800×g for 10min. Serum was separated and stored at −80°C until tested for IgG and pneumococcal serotypes trough levels. One five-millilitre sample of IVIG administered to each patient in the month before blood collection was also stored at 4°C until analysis. All patients were under IVIG replacement for over a year.Measurement of antibodies to S. pneumoniae by ELISAQuantification of IgG antibodies was performed by ELISA, in accordance with the protocol formulated by the W.H.O. available at <a id="intr0005" class="elsevierStyleInterRef" href="http://www.vaccine.uab.edu/">http://www.vaccine.uab.edu</a>.The ELISA for detection of antibodies against six serotypes of S. pneumoniae (1, 5, 6B, 9V, 14 and 19F, obtained from American Type Culture Collection – ATCC, Manassas, USA) was previously calibrated at the Research Laboratory of the Division of Pediatric Infectious Diseases of the Federal University of São Paulo.Human serum samples were mixed before analysis with C-polysaccharide (C-PS) (Statens Serum Institute, Copenhagen, Denmark) and 22F (ATCC) capsular polysaccharide (PS) to neutralise antibody binding to C-PS and other common contaminants present in the pneumococcal polysaccharide (PnPS) coating antigens. ELISA plates were coated with PnPS by adsorbing individual PnPS serotype antigens to microplates. Dilutions of absorbed human sera were then added to the ELISA plates. The serotype specific antibody bound to the ELISA plate was detected with anti-human IgG antibody conjugated with alkaline phosphatase, followed by addition of the substrate, p-nitrophenyl phosphate. The optical density of each well was measured at 405nm and 690nm using an ELISA plate reader. The antibody level of the human serum was calculated by interpolating the optical density of the sample wells to that of the standard serum (human anti-pneumococcal reference serum, lot 89-SF – Center for Biological Evaluation and Review, US Food and Drug Administration, Bethesda, MD, USA).For serotype 14, the same method was applied, but the substrate was incubated for 45min instead of the usual 120min.Protective antibody levels were considered to be ≥1.3μg/mL.<a class="elsevierStyleCrossRef" href="#bib0170">5</a>Statistical analysisIntervals between IVIG administration in individuals with and without infection were compared using Mann–Whitney test. Serum antibody levels and IVIG levels were compared using Kruskal–Wallis test, with differences among groups assessed by Student–Newman–Keuls comparison. Correlation between total IgG and specific antibodies for the six serotypes was tested using Pearson's correlation coefficient. For all analyses, BioEstat 5.0 software (Instituto de Desenvolvimento Sustentável Mamirauá, Tefé, Brazil) was employed. Statistical significance was set at p<0.05.ResultsThe median age of patients was 20.7 years and the median age at diagnosis was 8.0 years. The median IgG at PID diagnosis was 1.49g/L (range, 0.03–5.95g/L). Demographic characteristics of study patients are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Over the course of the study, the IVIG dose (median, 522mg/kg/month) remained unchanged for all patients. Most patients received more than one IVIG commercial preparation during the study, but never in the same infusion, because they depended on preparations provided by the Brazilian government. Thirty-eight lots of six different commercial IVIG preparations (Flebogamma®, Octagam®, Tegeline®, Immunoglobulin®, Endobulin® and Vigam®) were evaluated.Out of the 21 patients, 18 (85.7%) had some infection within the study period, with a median of three infections per patient. Sixty-two out of 64 infectious episodes (96.9%) were clinically classified as respiratory tract infections – such as sinusitis, otitis, pharyngitis, and pneumonia – or conjunctivitis (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). Any clinical manifestation of cough with secretion or change in the current secretion without a definitive diagnosis was considered as acute respiratory infection (ARI) and antibiotics were recommended. There were 4/64 (6.2%) episodes of pneumonia, but the pathogen was not identified, and 3/4 of these (75%) required hospitalisation (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). The four episodes of pneumonia occurred during the study period, but not at the time of blood sample collection. Thus, an assessment of serum antibody levels close to those pneumonia intervals was not possible.<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Seven out of 21 patients (33.3%) had pulmonary sequel and six (85.7%) were on antimicrobial prophylaxis with amoxicillin or azithromycin or ciprofloxacin or trimethoprim-sulfamethoxazole during the study period (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).Although the median concentration of all tested pneumococcal serotypes was above 1.3μg/mL in serum, the variation between minimum and maximum levels was very high, reaching more than 80 fold for some serotypes (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). Antibody levels below 1.3μg/mL were observed in 8/84 (9.5%) blood samples for serotype 1, 8/84 (9.5%) blood samples for serotype 5, 2/84 (2.4%) blood samples for serotype 6B and 3/84 (3.6%) blood samples for serotype 9V. Antibodies to serotypes 14 and 19F were above 1.3μg/mL in all evaluations. Antibody levels to serotype 14 were significantly higher than antibodies to the other five serotypes (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).<elsevierMultimedia ident="tbl0015"></elsevierMultimedia>Considering the four blood samples, only six out of 21 patients (28.6%) maintained antibodies above 1.3μg/mL for the six pneumococcal serotypes during the one-year period (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). Median IgG trough levels (676 versus 698mg/dL) and median number of infections during the study (2.5 versus 3.0) were similar in the groups of patients with and without serum samples with pneumococcal levels above 1.3μg/mL in all samples.Patients who received IVIG doses greater than 500mg/kg (n=14) were compared with those who received 500mg/kg of IVIG or less (n=7): antibody levels for the six serotypes analysed were higher in the group that received lower doses of IVIG (Mann–Whitney, p≤0.01 for all serotypes). Median pneumococcal levels for patients on IVIG doses >500mg/kg and ≤500mg/kg were the following, respectively. For serotype 1: 2.28 and 3.97; 5: 2.00 and 3.10; 6B: 3.92 and 5.76; 9V: 2.54 and 4.56; 14: 6.18 and 8.09; 19F: 4.33 and 7.20.Patients with XLA had higher pneumococcal antibody levels for serotypes 1, 6B and 14 (Mann–Whitney, serotype 1: p=0.04; 6B: p=0.04; 14: p=0.02) compared to the other patients, without difference in the dose of IVIG between them (Mann–Whitney, p=0.38). By contrast, antibody levels for the other pneumococcal serotypes (5, 9V and 19F) were similar to those observed in the other patients (Mann–Whitney, serotype 5: p=0.18; 9V: p=0.08; 19F: p=0.12).The most frequent IVIG administered to patients was Octagam® (Octapharma Pharmazeutika Produktionsges, Viena, Austria) (42/84; 50.0%). The other IVIG brands used were: 23/84 (24.4%) from Flebogamma 5%® (Grifols, S.A, Barcelona, Spain); 8/84 (9.5%) from Tegeline® (LFB Biomedicaments, Lille, France); 5/84 (5.9%) from Vigam® (BPL Bio Products Laboratory, Hertfordshire, United Kingdom); 4/84 (4.8%) from Endobulin® (Baxter, Vienna, Austria) and 2/84 (2.4%) from Blausiegel® (Korea Green Cross Corporation, Korea).All IVIG samples contained antibodies to each of the six different pneumococcal serotypes studied. However, a considerable variation in antibody levels to different serotypes was noted among the 38 lots of IVIG, reaching over 90% for serotypes 6B and 14 (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>). In one of the brands of IVIG, more than one lot had very low antibody levels. The pneumococcal serotype with the highest levels of antibodies in IVIG preparations was serotype 19F, and that was significantly different from the other serotypes (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>).<elsevierMultimedia ident="tbl0020"></elsevierMultimedia>Median total IgG serum levels were 7.91g/L (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> and <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). No correlation was found between IgG trough levels and pneumococcal specific antibodies for the six serotypes (Pearson's correlation coefficient, p>0.05) (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).<elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia>DiscussionReplacement therapy with IVIG is the main treatment for PID patients who do not produce antibodies, since it leads to a reduction in infection rates and prevents the most serious infections.<a class="elsevierStyleCrossRefs" href="#bib0155">2,13</a> Hence it is crucial that intravenous immunoglobulin preparations have adequate levels of antibodies against extracellular bacteria such as S. pneumoniae.<a class="elsevierStyleCrossRefs" href="#bib0195">10,14</a>However, the multiplicity of serotypes, the differences in methods used to analyse the specific antibodies to S. pneumoniae, together with the criteria used for the interpretation of these antibodies<a class="elsevierStyleCrossRef" href="#bib0170">5</a> are factors that make it difficult to analyse results from such studies.We chose three known PID diseases in which low IgG levels and lack of antibody production are present. Moreover, we believe that age is not a limitation of the study as antibody production by these patients is not age-dependent.During the 296 clinical visits of the study period, the vast majority of patients presented respiratory infections and antibiotics were prescribed in 52 situations. Respiratory infections are the most frequent infections in these patients even those treated with IVIG.<a class="elsevierStyleCrossRefs" href="#bib0220">15,16</a> Some patients with ARI might have had viral infections.<a class="elsevierStyleCrossRef" href="#bib0230">17</a> However, as viral episodes of infection may lead to secondary bacterial infection in patients with lung disease,<a class="elsevierStyleCrossRef" href="#bib0235">18</a> antibiotics were recommended in all cases.The recommended time interval for IVIG is 3–4 weeks and that was kept in the vast majority of our patients (median, 28 days; range, 21–34 days). The interval between infusions ranged from 26 to 50 days in another study that showed a common pattern in these patients.<a class="elsevierStyleCrossRef" href="#bib0240">19</a> The recommended dose for each patient was maintained during the study in accordance with other reference centres of PID<a class="elsevierStyleCrossRef" href="#bib0245">20</a> and patients with any lung disease received higher doses compared with patients without pulmonary sequels.Antibodies to pneumococcal serotypes 1, 5, 6B and 9V were present in levels below 1.3μg/mL in many patients in our study. Serotypes 14 and 19F are also important causes of pneumococcal invasive disease in our country,<a class="elsevierStyleCrossRef" href="#bib0250">21</a> but fortunately all patients presented protective antibody levels to these serotypes in all analysed samples. Altogether, the six pneumococcal serotypes analysed in this study represent 20.6% of S. pneumoniae isolated in adults and children over five years in Brazil in 2011.<a class="elsevierStyleCrossRef" href="#bib0250">21</a>Pneumococcal antibody levels were not lower in patients who received doses equal to or lower than 500mg/kg or in those diagnosed with XLA. Patients who are receiving lower IVIG doses are those who present mild disease without lung sequel and this could be a reason for a lower intake of IVIG. However, other factors might interfere with IgG catabolism. As reviewed by Bonilla,<a class="elsevierStyleCrossRef" href="#bib0255">22</a> the IgG catabolism is mediated by FcRn and higher cumulative IgG doses over time tend to be associated with a shorter half-life of IgG in serum.Different from previous studies, the behaviour of pneumococcal antibody levels was shown in a prospective way. In general, it is assumed that patients on regular IVIG treatment are provided with high antibody levels against varied pathogens and are protected. However, our results showed that the maintenance of antibodies above 1.3μg/mL during one year for all six serotypes was only observed in a minority of individuals (28.6%).Another very important issue was the opportunity this study provided to evaluate different brands of IVIG in the same group of patients. The analyses also show that there is a high variation of antibody concentrations in the samples studied. IVIG purification methods are manufacturer specific and unique with respect to specific conditions during fractionation and the combination of methods used to decrease aggregate formation, to remove proteins associated with adverse events, and to provide viral clearance.<a class="elsevierStyleCrossRef" href="#bib0260">23</a>The administration of IVIG results in a peak concentration of total IgG that decreases over time before the next infusion. The concentration of IgG in the serum immediately before the next infusion of IVIG is seen by most immunologists as an important guide to therapy<a class="elsevierStyleCrossRef" href="#bib0265">24</a> and a significant reduction in pneumonia incidence is associated with higher trough IgG levels in patients with antibody deficiency.<a class="elsevierStyleCrossRef" href="#bib0270">25</a> However, no correlation between total IgG levels and specific antibody levels were noted in our results, suggesting that high or adequate trough IgG levels might not always ensure protective antibody levels to different pathogens. Different results were observed when only one IVIG brand was used.<a class="elsevierStyleCrossRef" href="#bib0240">19</a>It was also not possible to correlate the occurrence of respiratory infections with pneumococcal antibody levels. Likewise, a previous attempt to correlate pneumococcal antibody levels with acute exacerbation in patients with chronic pulmonary diseases was not successful.<a class="elsevierStyleCrossRef" href="#bib0275">26</a> For PID patients these correlations are more difficult to establish: even in patients with recommended IgG levels (IgG >7.0g/L), suboptimal pneumococcal antibodies were observed.<a class="elsevierStyleCrossRef" href="#bib0280">27</a> Also, even when protective antibody levels are present in serum, patients with severe impaired antibody production are not fully protected from presenting some form of disease.<a class="elsevierStyleCrossRef" href="#bib0285">28</a>There is a wide variation in specific antibody levels in different IVIG brands and lots to different antigens.<a class="elsevierStyleCrossRefs" href="#bib0195">10,14,29</a> The variation in this study of pneumococcal antibodies in IVIG analysed was above 30% for several serotypes in the different brands and lots, a little bit higher when compared to the results from Lejtenyi and Mazer. However, these authors analysed only one brand of IVIG.<a class="elsevierStyleCrossRef" href="#bib0195">10</a> Interestingly, the higher antibody concentrations found for serotype 19F in IVIG preparations were not found when the patients’ serum samples were analysed: in these samples, antibodies to serotype 14 were usually higher than the other serotypes. This might indicate that assessing specific antibodies only in IVIG preparations cannot be sufficient to predict antibody concentrations in the patients’ serum.Therefore, despite the proven efficacy of IVIG, it would be interesting to monitor the causative pathogens of infections affecting these patients and the level of specific antibodies. This investigation could generate important data on the behaviour of specific antibodies in these patients.ConclusionPneumococcal antibodies are present in a high range of concentrations in sera from PID patients and also in IVIG preparations. Even maintaining a recommended IgG trough level, these patients can be susceptible to these bacteria and that may contribute to recurrent respiratory infections.Ethical disclosuresConfidentiality of dataThe authors declare that they have followed the protocols of their work centre on the publication of patient data and that all the patients included in the study have received sufficient information and have given their informed consent in writing to participate in that study.Right to privacy and informed consentThe authors have obtained the informed consent of the patients mentioned in the article. The author for correspondence is in possession of this document.Protection of human subjects and animals in researchThe authors declare that the procedures followed were in accordance with the regulations of the responsible Clinical Research Ethics Committee and in accordance with those of the World Medical Association and the Helsinki Declaration.Financial supportCAPES, a Brazilian Funding Agency.Conflict of interestThe authors declare no conflict of interest." "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres783844" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec782732" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 3 => array:3 [ "identificador" => "sec0010" "titulo" => "Patients and methods" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Collection of blood and IVIG samples" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Measurement of antibodies to S. pneumoniae by ELISA" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Statistical analysis" ] ] ] 4 => array:2 [ "identificador" => "sec0030" "titulo" => "Results" ] 5 => array:2 [ "identificador" => "sec0035" "titulo" => "Discussion" ] 6 => array:2 [ "identificador" => "sec0040" "titulo" => "Conclusion" ] 7 => array:3 [ "identificador" => "sec0045" "titulo" => "Ethical disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0050" "titulo" => "Confidentiality of data" ] 1 => array:2 [ "identificador" => "sec0055" "titulo" => "Right to privacy and informed consent" ] 2 => array:2 [ "identificador" => "sec0060" "titulo" => "Protection of human subjects and animals in research" ] ] ] 8 => array:2 [ "identificador" => "sec0065" "titulo" => "Financial support" ] 9 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflict of interest" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-02-10" "fechaAceptado" => "2016-04-27" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec782732" "palabras" => array:6 [ 0 => "Antibody deficiency" 1 => "Hypogammaglobinaemia" 2 => "Intravenous immunoglobulin" 3 => "Pneumococcal infection" 4 => "Primary immunodeficiency disease" 5 => "Streptococcus pneumoniae" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "BackgroundThis is a prospective study that assessed pneumococcal antibody levels in PID patients under intravenous immunoglobulin (IVIG) treatment using different brands. MethodsTwenty-one patients receiving regular IVIG every 28 days were invited to participate: 12 with common variable immunodeficiency, six with X-linked agammaglobulinaemia and three with hyper-IgM syndrome.One blood sample was collected from each patient just prior to IVIG administration at a three-month time interval during one year. A questionnaire was filled in with patient's demographic data and history of infections during the study period. Streptococcus pneumoniae antibodies against six serotypes (1, 5, 6B, 9V, 14 and 19F) were assessed by ELISA both in patients’ serum (trough levels) and in IVIG samples. ResultsMedian total IgG trough serum levels were 7.91g/L (range, 4.59–12.20). All patients had antibody levels above 0.35μg/mL to the six serotypes on all four measurements. However, only 28.6% of patients had pneumococcal antibodies for the six analysed serotypes above 1.3μg/mL on all four evaluations during the one-year period. No correlation was found between IgG trough levels and pneumococcal specific antibodies. Eighteen of the 21 patients (85.7%) had infections at some point during the 12-month follow-up, 62/64 (96.9%) clinically classified in respiratory tract infections, four of which were pneumonia. ConclusionsPneumococcal antibodies are present in a high range of concentrations in sera from PID patients and also in IVIG preparations. Even maintaining a recommended IgG trough level, these patients can be susceptible to these bacteria and that may contribute to recurrent respiratory infections." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] ] "multimedia" => array:6 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1114 "Ancho" => 1605 "Tamanyo" => 70332 ] ] "descripcion" => array:1 [ "en" => "Total IgG measured in serum samples of patients on regular use of intravenous immunoglobulin." ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1455 "Ancho" => 3345 "Tamanyo" => 245452 ] ] "descripcion" => array:1 [ "en" => "Correlation between total IgG and pneumococcal antibodies of six serotypes of pneumococcal measured in 84 serum samples of patients on regular use of intravenous immunoglobulin." ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Parameter \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Values \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Median age in years (range) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">20.7 (3–42) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Male gender (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11 (52.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Number of patients using antimicrobial prophylaxis (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 (28.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Median dose of IVIG administered to patients (range) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">550mg/kg (340–760) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Median serum trough IgG levels in patients (range) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.91g/L (4.6–12.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Median follow-up of each patient during study period in months (range) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13.9 (11.5–15.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1302785.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Demographic characteristics of study patients." ] ] 3 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Patients \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Visits to Immunology Clinic \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Infectious episodes \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Admission to hospital \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Pulmonary sequel \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Continuous antimicrobial prophylaxis \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Number of antimicrobial treatment \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Other medication \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 ARI/1 PMN/1 AOM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Topical steroid/Bronchodilator \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 sinusitis/1 ARI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 pharyngitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Corticosteroids/Bronchodilator \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 ARI/1 cutaneous infection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 ARI/1 AOM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Corticosteroids/Bronchodilator/Antidepressant \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 ARI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Bronchodilator/Corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 ARI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 ARI/1 AOM/1 sinusitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 urinary infection/2 ARI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 ARI/1 conjunctivitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 ARI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Antiviral \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 ARI/1 conjunctivitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Antihistamine drug \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 ARI/1 PMN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Bronchodilator/Corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 ARI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 ARI/1 PMN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 ARI/1 PMN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Antiviral \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 ARI/1 sinusitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="char" valign="top">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 ARI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">None \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1302783.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Antimicrobial prophylaxis prescribed but not taken by patient." ] ] ] "descripcion" => array:1 [ "en" => "Medical records of patients in the study period (AOM, acute otitis media; ARI, acute respiratory infection; PNM, pneumonia)." ] ] 4 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "na: not applicable." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Pneumococcal serotype \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="5" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Proportion of samples with pneumococcal antibodies >1.3mcg/mL</th><th class="td" title="table-head " align="left" valign="top" scope="col">Pneumococcal antibodies in sera \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col">Pneumococcal antibodies in IGIV \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">1st sample (n=21) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">2nd sample (n=21) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">3rd sample (n=21) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">4th sample (n=21) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">All 4 samples \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median and range (μg/mL) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median and range (μg/mg IgG) \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">95.2% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">80.9% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">85.7% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">61.9% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.8 (0.91–30.04) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.66 (0.04–1.34) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">85.7% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">76.2% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">71.4% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.2 (0.74–31.34) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.14 (0.01–0.42) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">6B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">95.2% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">95.2% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">90.5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4.6 (0.63–54.90) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.24 (0.02–1.12) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">9V \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">95.2% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">90.5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">85.7% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.7 (1.09–51.70) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.54 (0.17–1.37) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.7 (2.15–41.96) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.30 (0.09–2.08) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">19F \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4.8 (1.46–29.78) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.06 (0.30–2.19) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">All tested serotypes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">90.5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">71.1% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">57.1% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">28.6% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">na \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">na \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1302784.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Prospective immunological evaluation of patients on regular use of IGIV." ] ] 5 => array:8 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at4" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Brand \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 1</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 5</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 6B</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 9V</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 14</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 19F</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median Antibody level (μg/mg IgG) (Q1–Q3) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median Antibody level (μg/mg IgG) (Q1–Q3) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median Antibody level (μg/mg IgG) (Q1–Q3) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median Antibody level (μg/mg IgG) (Q1–Q3) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median Antibody level (μg/mg IgG) (Q1–Q3) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median Antibody level (μg/mg IgG) (Q1–Q3) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Octagam® n=16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.84 (0.77–1.00) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.61–1.34 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.16 (0.14–0.23) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.11–0.26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.25 (0.21–0.32) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.14–1.12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.76 (0.59–0.90) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.17–1.37 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.31 (0.28–0.39) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.25–2.07 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.37 (0.89–1.60) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.30–2.00 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Flebogamma® n=6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.34 (0.25–0.46) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.25–0.64 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.06 (0.05–0.07) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.05–0.09 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.07 (0.07–0.08) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.06–0.23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.4 (0.38–0.48) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.36–0.59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.17 (0.15–0.19) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.15–0.43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.90 (0.87–1.02) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.85–1.69 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Endobulin® n=3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.05 (0.04–0.07) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.04–0.08 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.01 (0.01–0.01) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.01–0.02 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.03 (0.02–0.03) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.02–0.03 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.28 (0.25–0.35) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.23–0.43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.11 (0.10–0.12) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.09–0.12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.55 (0.53–0.68) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.50–0.81 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Blausigel® n=2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.80 (0.77–0.82) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.75–0.85 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.14 (0.14–0.15) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.14–0.15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.21 (0.20–0.23) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.18–0.24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.98 (0.93–1.03) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.90–1.08 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.21 (0.18–0.25) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.15–0.28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.69 (1.44–1.94) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.19–2.19 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tegeline® n=9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.36 (0.24–0.57) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.13–0.99 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.01 (0.07–0.27) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.03–0.42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.57 (0.34–0.79) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.05–1.12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.41 (0.29–0.45) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.21–1.16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.60 (0.52–0.89) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.10–1.30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.90 (0.71–1.24) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.37–1.55 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Vigam® n=2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.88 (0.78–0.97) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.69–1.07 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.14 (0.10–0.18) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.05–0.23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.83 (0.77–0.89) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.70–0.95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.70 (0.61–0.80) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.52–0.89 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.99 (0.75–1.23) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.50–1.47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.52 (1.36–1.69) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.19–1.85 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="13" align="left" valign="top"></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Coefficient of variation (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="center" valign="top">54.86%</td><td class="td" title="table-entry " colspan="2" align="center" valign="top">66.70%</td><td class="td" title="table-entry " colspan="2" align="center" valign="top">93.28%</td><td class="td" title="table-entry " colspan="2" align="center" valign="top">52.01%</td><td class="td" title="table-entry " colspan="2" align="center" valign="top">93.60%</td><td class="td" title="table-entry " colspan="2" align="center" valign="top">42.98%</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1302786.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Pneumococcal antibodies in different lots of commercially available preparations of intravenous immunoglobulin used in study." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:29 [ 0 => array:3 [ "identificador" => "bib0150" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.J. Fried" 1 => "F.A. Bonilla" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/CMR.00001-09" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Rev" "fecha" => "2009" "volumen" => "22" "paginaInicial" => "396" "paginaFinal" => "414" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19597006" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0155" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P.J. Busse" 1 => "S. Razvi" 2 => "C. Cunningham-Rundles" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2002" "volumen" => "109" "paginaInicial" => "1001" "paginaFinal" => "1004" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12063531" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0160" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infections in 252 patients with common variable immunodeficiency" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Oksenhendler" 1 => "L. Gérard" 2 => "C. Fieschi" 3 => "M. Malphettes" 4 => "G. Mouillot" 5 => "R. Jaussaud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/587669" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2008" "volumen" => "46" "paginaInicial" => "1547" "paginaFinal" => "1554" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18419489" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0165" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.R. Siber" 1 => "I. Chang" 2 => "S. Baker" 3 => "P. Fernsten" 4 => "K.L. O’Brien" 5 => "M. Santosham" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2007.01.119" "Revista" => array:6 [ "tituloSerie" => "Vaccine" "fecha" => "2007" "volumen" => "25" "paginaInicial" => "3816" "paginaFinal" => "3826" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17368878" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0170" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Post-immunization pneumococcal antibody titers and IgG subclasses" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R.U. Sorensen" 1 => "H. Hidalgo" 2 => "C. Moore" 3 => "L.E. Leiva" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/(SICI)1099-0496(199609)22:3<167::AID-PPUL5>3.0.CO;2-M" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "1996" "volumen" => "22" "paginaInicial" => "167" "paginaFinal" => "173" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8893255" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0175" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The immunological basis for immunization series: module 12: pneumococcal vaccines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "H. Käyhty" 1 => "A. Nurkka" 2 => "A. Soininen" 3 => "M. Väkeväinen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Immun Vaccines Biol" "fecha" => "2009" "volumen" => "12" "paginaInicial" => "1" "paginaFinal" => "61" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0180" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "B. Bayrakci" 1 => "F. Ersoy" 2 => "O. Sanal" 3 => "S. Kilic" 4 => "A. Metin" 5 => "I. Tezcan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Turk J Pediatr" "fecha" => "2005" "volumen" => "47" "paginaInicial" => "239" "paginaFinal" => "246" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16250308" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0185" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.S. Orange" 1 => "E.M. Hossny" 2 => "C.R. Weiler" 3 => "M. Ballow" 4 => "M. Berger" 5 => "F.A. Bonilla" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2006" "volumen" => "117" "paginaInicial" => "525" "paginaFinal" => "553" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0190" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IgG antibody reactive with five serotypes of Streptococcus pneumoniae in commercial intravenous immunoglobulin preparations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R.J. Hamill" 1 => "D.M. Musher" 2 => "J.E. Groover" 3 => "P.J. Zavell" 4 => "D.A. Watson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "1991" "volumen" => "166" "paginaInicial" => "38" "paginaFinal" => "42" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1607706" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0195" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D. Lejtenyi" 1 => "B. Mazer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2007.11.001" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2008" "volumen" => "121" "paginaInicial" => "254" "paginaFinal" => "255" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18206511" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0200" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A.P. Knutsen" 1 => "L.E. Leiva" 2 => "C. Caruthers" 3 => "J. Rodrigues" 4 => "R.U. Sorensen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/cei.12665" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Immunol" "fecha" => "2015" "volumen" => "182" "paginaInicial" => "51" "paginaFinal" => "56" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26230522" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0205" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantitation of antibodies in the sera of immunodeficient patients receiving monthly intravenous immune globulin (IVIg)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.M. Pieretti" 1 => "C. Cunningham-Rundles" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2009" "volumen" => "123" "paginaInicial" => "S14" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0210" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Quartier" 1 => "M. Debré" 2 => "J. De Blic" 3 => "R. de Sauverzac" 4 => "N. Sayegh" 5 => "N. Jabado" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Pediatr" "fecha" => "1999" "volumen" => "134" "paginaInicial" => "589" "paginaFinal" => "596" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10228295" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0215" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.G. Mikolajczyk" 1 => "N.F. Concepcion" 2 => "T. Wang" 3 => "D. Frazier" 4 => "B. Golding" 5 => "C.E. Frasch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/CDLI.11.6.1158-1164.2004" "Revista" => array:6 [ "tituloSerie" => "Clin Diagn Lab Immunol" "fecha" => "2004" "volumen" => "11" "paginaInicial" => "1158" "paginaFinal" => "1164" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15539522" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0220" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Survey of infection in patients receiving antibody replacement treatment for immune deficiency" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.J. Pettit" 1 => "H. Bourne" 2 => "G.P. Spickett" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Clin Pathol" "fecha" => "2002" "volumen" => "55" "paginaInicial" => "577" "paginaFinal" => "580" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12147649" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0225" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infections in 252 patients with common variable immunodeficiency" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "DEFI Study Group" "etal" => true "autores" => array:6 [ 0 => "E. Oksenhendler" 1 => "L. Gérard" 2 => "C. Fieschi" 3 => "M. Malphettes" 4 => "G. Mouillot" 5 => "R. Jaussaud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/587669" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2008" "volumen" => "46" "paginaInicial" => "1547" "paginaFinal" => "1554" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18419489" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0230" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Frequency and clinical outcome of respiratory viral infections and mixed viral-bacterial infections in children with cancer, fever and neutropenia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.P. Torres" 1 => "Y. Labraña" 2 => "C. Ibañez" 3 => "P. Kasaneva" 4 => "M.J. Farfán" 5 => "V. De la Maza" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/INF.0b013e31825c4b7e" "Revista" => array:6 [ "tituloSerie" => "Pediatr Infect Dis J" "fecha" => "2012" "volumen" => "31" "paginaInicial" => "889" "paginaFinal" => "893" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22565292" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0235" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infection as a comorbidity of COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "S. Sethi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00081409" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2010" "volumen" => "35" "paginaInicial" => "1209" "paginaFinal" => "1215" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20513910" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0240" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pneumococcal antibody levels in children with PID receiving immunoglobulin" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Tuerlinckx" 1 => "B. Florkin" 2 => "A. Ferster" 3 => "I. De Schutter" 4 => "C. Chantrain" 5 => "F. Haerynck" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1542/peds.2013-1155" "Revista" => array:6 [ "tituloSerie" => "Pediatrics" "fecha" => "2014" "volumen" => "133" "paginaInicial" => "e154" "paginaFinal" => "e162" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24366995" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0245" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical picture and treatment of 2212 patients with common variable immunodeficiency" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "European Society for Immunodeficiencies Registry Working Party" "etal" => true "autores" => array:6 [ 0 => "B. Gathmann" 1 => "N. Mahlaoui" 2 => "L. Gérard" 3 => "E. Oksenhendler" 4 => "K. Warnatz" 5 => "I. Schulze" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2013.12.1077" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2014" "volumen" => "134" "paginaInicial" => "116" "paginaFinal" => "126" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24582312" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0250" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "378 pp." "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Informe Regional de SIREVA II, 2011: datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Organización Panamericana de la Salud" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2012" "editorial" => "OPAS" "editorialLocalizacion" => "Washington, DC" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0255" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F.A. Bonilla" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.iac.2008.06.006" "Revista" => array:6 [ "tituloSerie" => "Immunol Allergy Clin North Am" "fecha" => "2008" "volumen" => "28" "paginaInicial" => "803" "paginaFinal" => "819" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18940575" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0260" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intravenous immune globulins: therapeutic, pharmaceutical, & cost considerations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Siegel" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pharm Pract" "fecha" => "2001" "volumen" => "28" "paginaInicial" => "11" "paginaFinal" => "13" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0265" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.L. Yong" 1 => "J. Boyle" 2 => "M. Ballow" 3 => "M. Boyle" 4 => "M. Berger" 5 => "J. Bleesing" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clim.2009.10.003" "Revista" => array:6 [ "tituloSerie" => "Clin Immunol" "fecha" => "2010" "volumen" => "135" "paginaInicial" => "255" "paginaFinal" => "263" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19914873" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0270" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.S. Orange" 1 => "W.J. Grossman" 2 => "R.J. Navickis" 3 => "M.M. Wilkes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clim.2010.06.012" "Revista" => array:6 [ "tituloSerie" => "Clin Immunol" "fecha" => "2010" "volumen" => "137" "paginaInicial" => "21" "paginaFinal" => "30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20675197" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0275" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.T. Yerkovich" 1 => "B.J. Hales" 2 => "M.L. Carroll" 3 => "J.G. Burel" 4 => "M.A. Towers" 5 => "D.J. Smith" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2466-12-37" "Revista" => array:5 [ "tituloSerie" => "BMC Pulm Med" "fecha" => "2012" "volumen" => "12" "paginaInicial" => "37" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22849333" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0280" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathogen-specific IgG antibody levels in patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "I. Chua" 1 => "M. Lagos" 2 => "B.M. Cjarambolous" 3 => "S. Workman" 4 => "R. Chee" 5 => "B. Grimbacher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2011.01.035" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2011" "volumen" => "127" "paginaInicial" => "1410" "paginaFinal" => "1411" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21376379" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0285" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Protective levels of Varicella-Zoster antibody did not effectively prevent chickenpox in an X-linked agammaglobulinemia patient" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F.A. Nobre" 1 => "I.G. Gonzalez" 2 => "M.I. Moraes-Pinto" 3 => "B.T. Costa-Carvalho" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1590/S0036-46652015000500017" "Revista" => array:6 [ "tituloSerie" => "Rev Inst Med Trop Sao Paulo" "fecha" => "2015" "volumen" => "57" "paginaInicial" => "455" "paginaFinal" => "457" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26603238" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0290" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F.A. Nobre" 1 => "I.G. Gonzalez" 2 => "R.M. Simão" 3 => "M.I. de Moraes-Pinto" 4 => "B.T. Costa-Carvalho" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2172-15-26" "Revista" => array:5 [ "tituloSerie" => "BMC Immunol" "fecha" => "2014" "volumen" => "15" "paginaInicial" => "26" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24952415" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03010546/0000004500000001/v1_201612300037/S0301054616300763/v1_201612300037/en/main.assets" "Apartado" => array:4 [ "identificador" => "5554" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/03010546/0000004500000001/v1_201612300037/S0301054616300763/v1_201612300037/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0301054616300763?idApp=UINPBA00004N"]

Statistics

Original Article

R.M. Simão-Gurgea, B.T. Costa-Carvalhob, F.A. Nobreb, I.G.S. Gonzalezb, M.I. de Moraes-Pintoa,

Corresponding author

m.isabelmp@uol.com.br

Corresponding author.

a Division of Pediatric Infectious Diseases, Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, SP, Brazil

b Division of Allergy Clinical Immunology and Rheumatology, Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, SP, Brazil

Read

1623

Times
was read the article

321

Total PDF

1302

Total HTML

Share statistics

 array:23 [
  "pii" => "S0301054616300763"
  "issn" => "03010546"
  "doi" => "10.1016/j.aller.2016.04.014"
  "estado" => "S300"
  "fechaPublicacion" => "2017-01-01"
  "aid" => "774"
  "copyright" => "SEICAP"
  "copyrightAnyo" => "2016"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "Allergol  Immunopathol &#40;Madr&#41;. 2017;45:55-62"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 30
    "formatos" => array:3 [
      "EPUB" => 8
      "HTML" => 11
      "PDF" => 11
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0301054616301057"
    "issn" => "03010546"
    "doi" => "10.1016/j.aller.2016.06.005"
    "estado" => "S300"
    "fechaPublicacion" => "2017-01-01"
    "aid" => "789"
    "copyright" => "SEICAP"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Allergol  Immunopathol &#40;Madr&#41;. 2017;45:63-8"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 24
      "formatos" => array:3 [
        "EPUB" => 3
        "HTML" => 11
        "PDF" => 10
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Efficacy of parthenolide on lung histopathology in a murine model of asthma"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "63"
          "paginaFinal" => "68"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2148
              "Ancho" => 3295
              "Tamanyo" => 1413667
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Light and electron microscopic findings of study groups&#46; I&#59; control &#40;n&#58;7&#41;&#44; II&#59; placebo &#40;n&#58;7&#41;&#44; III&#59; dexamethasone &#40;n&#58;7&#41;&#44; IV&#59; parthenolide &#40;n&#58;7&#41;&#44; V&#59; parthenolide and dexamethasone &#40;n&#58;7&#41;&#44; A&#59; H&#38;E&#44; B&#59; PAS&#44; C&#59; Toluidine staining&#46; &#40;A&#41; Arrow with two heads&#59; sub-epithelial smooth muscle thickening&#44; &#42; peribronchial mononuclear cell infiltration&#46; &#40;B&#41; arrows&#59; goblet cells &#40;C&#41; arrows&#59; mast cells&#46; &#40;D&#41; Electron microscopic views&#46; Increased goblet cells in placebo group &#40;Gc&#41;&#44; smooth muscle thickening &#40;Sm&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Z&#46; Ar&#305;kan-Ayy&#305;ld&#305;z, M&#46; Karaman, S&#46; &#214;zbal, A&#46; Ba&#287;r&#305;yan&#305;k, O&#46; Yilmaz, &#214;&#46; Karaman, N&#46; Uzuner"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "Z&#46;"
              "apellidos" => "Ar&#305;kan-Ayy&#305;ld&#305;z"
            ]
            1 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Karaman"
            ]
            2 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "&#214;zbal"
            ]
            3 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Ba&#287;r&#305;yan&#305;k"
            ]
            4 => array:2 [
              "nombre" => "O&#46;"
              "apellidos" => "Yilmaz"
            ]
            5 => array:2 [
              "nombre" => "&#214;&#46;"
              "apellidos" => "Karaman"
            ]
            6 => array:2 [
              "nombre" => "N&#46;"
              "apellidos" => "Uzuner"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0301054616301057?idApp=UINPBA00004N"
    "url" => "/03010546/0000004500000001/v1_201612300037/S0301054616301057/v1_201612300037/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0301054616300970"
    "issn" => "03010546"
    "doi" => "10.1016/j.aller.2016.06.004"
    "estado" => "S300"
    "fechaPublicacion" => "2017-01-01"
    "aid" => "784"
    "copyright" => "SEICAP"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Allergol  Immunopathol &#40;Madr&#41;. 2017;45:48-54"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 40
      "formatos" => array:2 [
        "HTML" => 31
        "PDF" => 9
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Food allergy in Catalonia&#58; Clinical manifestations and its association with airborne allergens"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "48"
          "paginaFinal" => "54"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0015"
          "etiqueta" => "Figure 3"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr3.jpeg"
              "Alto" => 2191
              "Ancho" => 1571
              "Tamanyo" => 173317
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Clinical manifestations of the main food&#47;food groups elicitors of allergic reactions&#46; GIS&#58; Gastrointestinal symptoms&#59; OAS&#58; oral allergy syndrome&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46; S&#225;nchez-L&#243;pez, V&#46; G&#225;zquez, N&#46; Rubira, L&#46; Valdesoiro, M&#46; Guilarte, A&#46; Garcia-Moral, N&#46; Depreux, L&#46; Soto-Retes, M&#46; De Molina, O&#46; Luengo, R&#46; Lleonart, M&#46; Basaga&#241;a"
          "autores" => array:12 [
            0 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "S&#225;nchez-L&#243;pez"
            ]
            1 => array:2 [
              "nombre" => "V&#46;"
              "apellidos" => "G&#225;zquez"
            ]
            2 => array:2 [
              "nombre" => "N&#46;"
              "apellidos" => "Rubira"
            ]
            3 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Valdesoiro"
            ]
            4 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Guilarte"
            ]
            5 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Garcia-Moral"
            ]
            6 => array:2 [
              "nombre" => "N&#46;"
              "apellidos" => "Depreux"
            ]
            7 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Soto-Retes"
            ]
            8 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "De Molina"
            ]
            9 => array:2 [
              "nombre" => "O&#46;"
              "apellidos" => "Luengo"
            ]
            10 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Lleonart"
            ]
            11 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Basaga&#241;a"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0301054616300970?idApp=UINPBA00004N"
    "url" => "/03010546/0000004500000001/v1_201612300037/S0301054616300970/v1_201612300037/en/main.assets"
  ]
  "en" => array:18 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
    "titulo" => "Prospective evaluation of <span class="elsevierStyleItalic">Streptococcus pneumoniae</span> serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "55"
        "paginaFinal" => "62"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "R&#46;M&#46; Sim&#227;o-Gurge, B&#46;T&#46; Costa-Carvalho, F&#46;A&#46; Nobre, I&#46;G&#46;S&#46; Gonzalez, M&#46;I&#46; de Moraes-Pinto"
        "autores" => array:5 [
          0 => array:3 [
            "nombre" => "R&#46;M&#46;"
            "apellidos" => "Sim&#227;o-Gurge"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "B&#46;T&#46;"
            "apellidos" => "Costa-Carvalho"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "F&#46;A&#46;"
            "apellidos" => "Nobre"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "I&#46;G&#46;S&#46;"
            "apellidos" => "Gonzalez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          4 => array:4 [
            "nombre" => "M&#46;I&#46;"
            "apellidos" => "de Moraes-Pinto"
            "email" => array:1 [
              0 => "m&#46;isabelmp&#64;uol&#46;com&#46;br"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Division of Pediatric Infectious Diseases&#44; Department of Pediatrics&#44; Universidade Federal de S&#227;o Paulo&#44; S&#227;o Paulo&#44; SP&#44; Brazil"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Division of Allergy Clinical Immunology and Rheumatology&#44; Department of Pediatrics&#44; Universidade Federal de S&#227;o Paulo&#44; S&#227;o Paulo&#44; SP&#44; Brazil"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1455
            "Ancho" => 3345
            "Tamanyo" => 245452
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Correlation between total IgG and pneumococcal antibodies of six serotypes of pneumococcal measured in 84 serum samples of patients on regular use of intravenous immunoglobulin&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The main clinical features of patients with hypogammaglobinaemia are recurrent infections of the respiratory tract with <span class="elsevierStyleItalic">Streptococcus pneumoniae</span> being the most frequent isolated bacterium&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">1</span></a> Long-term administration of immunoglobulin reduces the incidence of infection&#46; However&#44; some patients with common variable immunodeficiency &#40;CVID&#41; may continue to experience upper respiratory tract infections &#40;URTIs&#41; that lead to permanent lung damage&#44; and the optimal trough level for serum IgG remains under discussion&#46;<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">2&#44;3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The minimum concentration of serotype-specific <span class="elsevierStyleItalic">S&#46; pneumoniae</span> antibodies considered to be protective is widely debated&#46; The World Health Organization &#40;W&#46;H&#46;O&#46;&#41; considers the concentration of 0&#46;35<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL as protective for invasive pneumococcal disease in healthy children&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">4</span></a> However&#44; individuals with recurrent infections may require higher antibody levels such as 1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL for protection&#46;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">5</span></a> Moreover&#44; antibody concentrations required for the prevention of pneumonia&#44; otitis media or colonisation have yet to be established&#46;<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">4&#44;6</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Over the past two decades&#44; administration of exogenous pooled human immunoglobulin for intravenous use has become an important therapy in clinical medicine for patients with antibody deficiencies&#46; Passive immunisation by intravenous immunoglobulin &#40;IVIG&#41; has been shown to reduce infections in these patients&#44; especially those from encapsulated bacteria such as <span class="elsevierStyleItalic">S&#46; pneumoniae</span> and <span class="elsevierStyleItalic">Haemophilus influenzae</span> type b &#40;Hib&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">7&#44;8</span></a> Antibodies to <span class="elsevierStyleItalic">S&#46; pneumoniae</span> have been quantified in IVIG samples in a few studies&#44; without concomitant serum antibody level assessment&#44;<a class="elsevierStyleCrossRefs" href="#bib0190"><span class="elsevierStyleSup">9&#44;10</span></a> and some were quantified in sera only&#46;<a class="elsevierStyleCrossRefs" href="#bib0200"><span class="elsevierStyleSup">11&#44;12</span></a> Therefore&#44; monitoring antibody levels in these patients is necessary&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">The goal of this study was to evaluate serum antibody levels to <span class="elsevierStyleItalic">S&#46; pneumoniae</span> in patients with impaired production of IgG antibodies in regular use of IVIG replacement and to correlate these levels to IVIG preparations as well as to infectious episodes in each patient during the study period&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Patients and methods</span><p id="par0025" class="elsevierStylePara elsevierViewall">This is a prospective study approved by the Ethics Committee of the Federal University of S&#227;o Paulo that is in accordance with the World Medical Association and the Helsinki Declaration&#46; Twenty-one patients on regular IVIG replacement therapy were evaluated&#58; 12 with CVID&#44; six with X-linked agammaglobulinaemia &#40;XLA&#41; and three with hyper-IgM syndrome &#40;HIM&#41;&#46; Administration of IVIG was performed at intervals of 28 days &#40;range&#44; 21&#8211;34 days&#41;&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">At the beginning of the study&#44; a questionnaire was filled in with the following data&#58; date of birth&#44; gender&#44; diagnosis of immunodeficiency&#44; age at diagnosis&#44; period of treatment&#44; dose of IVIG&#46; During the study&#44; episodes of infections and antibiotic administration were also recorded&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Two of the three hyper-IgM patients had absence of pneumococcal antibodies after vaccine and the third had an early diagnosis and was not immunised&#46; Out of the 12 CVID patients&#44; eight had absence of antibodies to polysaccharide antigens and in four of them these antibodies were not tested but IgG levels were less than 0&#46;4<span class="elsevierStyleHsp" style=""></span>g&#47;L at diagnosis&#46; As XLA patients do not produce antibodies&#44; they were not tested before IVIG replacement therapy initiation&#46;</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Collection of blood and IVIG samples</span><p id="par0040" class="elsevierStylePara elsevierViewall">After written informed consent and immediately before IVIG infusion&#44; a 10<span class="elsevierStyleHsp" style=""></span>mL blood sample was collected totalling 84 samples that were centrifuged at 800<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">g</span> for 10<span class="elsevierStyleHsp" style=""></span>min&#46; Serum was separated and stored at &#8722;80<span class="elsevierStyleHsp" style=""></span>&#176;C until tested for IgG and pneumococcal serotypes trough levels&#46; One five-millilitre sample of IVIG administered to each patient in the month before blood collection was also stored at 4<span class="elsevierStyleHsp" style=""></span>&#176;C until analysis&#46; All patients were under IVIG replacement for over a year&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Measurement of antibodies to <span class="elsevierStyleItalic">S&#46; pneumoniae</span> by ELISA</span><p id="par0045" class="elsevierStylePara elsevierViewall">Quantification of IgG antibodies was performed by ELISA&#44; in accordance with the protocol formulated by the W&#46;H&#46;O&#46; available at <a id="intr0005" class="elsevierStyleInterRef" href="http://www.vaccine.uab.edu/">http&#58;&#47;&#47;www&#46;vaccine&#46;uab&#46;edu</a>&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">The ELISA for detection of antibodies against six serotypes of <span class="elsevierStyleItalic">S&#46; pneumoniae</span> &#40;1&#44; 5&#44; 6B&#44; 9V&#44; 14 and 19F&#44; obtained from American Type Culture Collection &#8211; ATCC&#44; Manassas&#44; USA&#41; was previously calibrated at the Research Laboratory of the Division of Pediatric Infectious Diseases of the Federal University of S&#227;o Paulo&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Human serum samples were mixed before analysis with C-polysaccharide &#40;C-PS&#41; &#40;Statens Serum Institute&#44; Copenhagen&#44; Denmark&#41; and 22F &#40;ATCC&#41; capsular polysaccharide &#40;PS&#41; to neutralise antibody binding to C-PS and other common contaminants present in the pneumococcal polysaccharide &#40;PnPS&#41; coating antigens&#46; ELISA plates were coated with PnPS by adsorbing individual PnPS serotype antigens to microplates&#46; Dilutions of absorbed human sera were then added to the ELISA plates&#46; The serotype specific antibody bound to the ELISA plate was detected with anti-human IgG antibody conjugated with alkaline phosphatase&#44; followed by addition of the substrate&#44; <span class="elsevierStyleItalic">p</span>-nitrophenyl phosphate&#46; The optical density of each well was measured at 405<span class="elsevierStyleHsp" style=""></span>nm and 690<span class="elsevierStyleHsp" style=""></span>nm using an ELISA plate reader&#46; The antibody level of the human serum was calculated by interpolating the optical density of the sample wells to that of the standard serum &#40;human anti-pneumococcal reference serum&#44; lot 89-SF &#8211; Center for Biological Evaluation and Review&#44; US Food and Drug Administration&#44; Bethesda&#44; MD&#44; USA&#41;&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">For serotype 14&#44; the same method was applied&#44; but the substrate was incubated for 45<span class="elsevierStyleHsp" style=""></span>min instead of the usual 120<span class="elsevierStyleHsp" style=""></span>min&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">Protective antibody levels were considered to be &#8805;1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL&#46;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">5</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Statistical analysis</span><p id="par0070" class="elsevierStylePara elsevierViewall">Intervals between IVIG administration in individuals with and without infection were compared using Mann&#8211;Whitney test&#46; Serum antibody levels and IVIG levels were compared using Kruskal&#8211;Wallis test&#44; with differences among groups assessed by Student&#8211;Newman&#8211;Keuls comparison&#46; Correlation between total IgG and specific antibodies for the six serotypes was tested using Pearson&#39;s correlation coefficient&#46; For all analyses&#44; BioEstat 5&#46;0 software &#40;Instituto de Desenvolvimento Sustent&#225;vel Mamirau&#225;&#44; Tef&#233;&#44; Brazil&#41; was employed&#46; Statistical significance was set at <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;05&#46;</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Results</span><p id="par0075" class="elsevierStylePara elsevierViewall">The median age of patients was 20&#46;7 years and the median age at diagnosis was 8&#46;0 years&#46; The median IgG at PID diagnosis was 1&#46;49<span class="elsevierStyleHsp" style=""></span>g&#47;L &#40;range&#44; 0&#46;03&#8211;5&#46;95<span class="elsevierStyleHsp" style=""></span>g&#47;L&#41;&#46; Demographic characteristics of study patients are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">Over the course of the study&#44; the IVIG dose &#40;median&#44; 522<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;month&#41; remained unchanged for all patients&#46; Most patients received more than one IVIG commercial preparation during the study&#44; but never in the same infusion&#44; because they depended on preparations provided by the Brazilian government&#46; Thirty-eight lots of six different commercial IVIG preparations &#40;Flebogamma<span class="elsevierStyleSup">&#174;</span>&#44; Octagam<span class="elsevierStyleSup">&#174;</span>&#44; Tegeline<span class="elsevierStyleSup">&#174;</span>&#44; Immunoglobulin<span class="elsevierStyleSup">&#174;</span>&#44; Endobulin<span class="elsevierStyleSup">&#174;</span> and Vigam<span class="elsevierStyleSup">&#174;</span>&#41; were evaluated&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">Out of the 21 patients&#44; 18 &#40;85&#46;7&#37;&#41; had some infection within the study period&#44; with a median of three infections per patient&#46; Sixty-two out of 64 infectious episodes &#40;96&#46;9&#37;&#41; were clinically classified as respiratory tract infections &#8211; such as sinusitis&#44; otitis&#44; pharyngitis&#44; and pneumonia &#8211; or conjunctivitis &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46; Any clinical manifestation of cough with secretion or change in the current secretion without a definitive diagnosis was considered as acute respiratory infection &#40;ARI&#41; and antibiotics were recommended&#46; There were 4&#47;64 &#40;6&#46;2&#37;&#41; episodes of pneumonia&#44; but the pathogen was not identified&#44; and 3&#47;4 of these &#40;75&#37;&#41; required hospitalisation &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46; The four episodes of pneumonia occurred during the study period&#44; but not at the time of blood sample collection&#46; Thus&#44; an assessment of serum antibody levels close to those pneumonia intervals was not possible&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0090" class="elsevierStylePara elsevierViewall">Seven out of 21 patients &#40;33&#46;3&#37;&#41; had pulmonary sequel and six &#40;85&#46;7&#37;&#41; were on antimicrobial prophylaxis with amoxicillin or azithromycin or ciprofloxacin or trimethoprim-sulfamethoxazole during the study period &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">Although the median concentration of all tested pneumococcal serotypes was above 1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL in serum&#44; the variation between minimum and maximum levels was very high&#44; reaching more than 80 fold for some serotypes &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46; Antibody levels below 1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL were observed in 8&#47;84 &#40;9&#46;5&#37;&#41; blood samples for serotype 1&#44; 8&#47;84 &#40;9&#46;5&#37;&#41; blood samples for serotype 5&#44; 2&#47;84 &#40;2&#46;4&#37;&#41; blood samples for serotype 6B and 3&#47;84 &#40;3&#46;6&#37;&#41; blood samples for serotype 9V&#46; Antibodies to serotypes 14 and 19F were above 1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL in all evaluations&#46; Antibody levels to serotype 14 were significantly higher than antibodies to the other five serotypes &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">Considering the four blood samples&#44; only six out of 21 patients &#40;28&#46;6&#37;&#41; maintained antibodies above 1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL for the six pneumococcal serotypes during the one-year period &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46; Median IgG trough levels &#40;676 versus 698<span class="elsevierStyleHsp" style=""></span>mg&#47;dL&#41; and median number of infections during the study &#40;2&#46;5 versus 3&#46;0&#41; were similar in the groups of patients with and without serum samples with pneumococcal levels above 1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL in all samples&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">Patients who received IVIG doses greater than 500<span class="elsevierStyleHsp" style=""></span>mg&#47;kg &#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>14&#41; were compared with those who received 500<span class="elsevierStyleHsp" style=""></span>mg&#47;kg of IVIG or less &#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>7&#41;&#58; antibody levels for the six serotypes analysed were higher in the group that received lower doses of IVIG &#40;Mann&#8211;Whitney&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#8804;<span class="elsevierStyleHsp" style=""></span>0&#46;01 for all serotypes&#41;&#46; Median pneumococcal levels for patients on IVIG doses &#62;500<span class="elsevierStyleHsp" style=""></span>mg&#47;kg and &#8804;500<span class="elsevierStyleHsp" style=""></span>mg&#47;kg were the following&#44; respectively&#46; For serotype <span class="elsevierStyleBold">1</span>&#58; 2&#46;28 and 3&#46;97&#59; <span class="elsevierStyleBold">5</span>&#58; 2&#46;00 and 3&#46;10&#59; <span class="elsevierStyleBold">6B</span>&#58; 3&#46;92 and 5&#46;76&#59; <span class="elsevierStyleBold">9V</span>&#58; 2&#46;54 and 4&#46;56&#59; <span class="elsevierStyleBold">14</span>&#58; 6&#46;18 and 8&#46;09&#59; <span class="elsevierStyleBold">19F</span>&#58; 4&#46;33 and 7&#46;20&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Patients with XLA had higher pneumococcal antibody levels for serotypes 1&#44; 6B and 14 &#40;Mann&#8211;Whitney&#44; serotype <span class="elsevierStyleBold">1</span>&#58; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;04&#59; <span class="elsevierStyleBold">6B</span>&#58; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;04&#59; <span class="elsevierStyleBold">14</span>&#58; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;02&#41; compared to the other patients&#44; without difference in the dose of IVIG between them &#40;Mann&#8211;Whitney&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;38&#41;&#46; By contrast&#44; antibody levels for the other pneumococcal serotypes &#40;5&#44; 9V and 19F&#41; were similar to those observed in the other patients &#40;Mann&#8211;Whitney&#44; serotype <span class="elsevierStyleBold">5</span>&#58; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;18&#59; <span class="elsevierStyleBold">9V</span>&#58; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;08&#59; <span class="elsevierStyleBold">19F</span>&#58; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;12&#41;&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">The most frequent IVIG administered to patients was Octagam<span class="elsevierStyleSup">&#174;</span> &#40;Octapharma Pharmazeutika Produktionsges&#44; Viena&#44; Austria&#41; &#40;42&#47;84&#59; 50&#46;0&#37;&#41;&#46; The other IVIG brands used were&#58; 23&#47;84 &#40;24&#46;4&#37;&#41; from Flebogamma 5&#37;<span class="elsevierStyleSup">&#174;</span> &#40;Grifols&#44; S&#46;A&#44; Barcelona&#44; Spain&#41;&#59; 8&#47;84 &#40;9&#46;5&#37;&#41; from Tegeline<span class="elsevierStyleSup">&#174;</span> &#40;LFB Biomedicaments&#44; Lille&#44; France&#41;&#59; 5&#47;84 &#40;5&#46;9&#37;&#41; from Vigam<span class="elsevierStyleSup">&#174;</span> &#40;BPL Bio Products Laboratory&#44; Hertfordshire&#44; United Kingdom&#41;&#59; 4&#47;84 &#40;4&#46;8&#37;&#41; from Endobulin<span class="elsevierStyleSup">&#174;</span> &#40;Baxter&#44; Vienna&#44; Austria&#41; and 2&#47;84 &#40;2&#46;4&#37;&#41; from Blausiegel<span class="elsevierStyleSup">&#174;</span> &#40;Korea Green Cross Corporation&#44; Korea&#41;&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">All IVIG samples contained antibodies to each of the six different pneumococcal serotypes studied&#46; However&#44; a considerable variation in antibody levels to different serotypes was noted among the 38 lots of IVIG&#44; reaching over 90&#37; for serotypes 6B and 14 &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#41;&#46; In one of the brands of IVIG&#44; more than one lot had very low antibody levels&#46; The pneumococcal serotype with the highest levels of antibodies in IVIG preparations was serotype 19F&#44; and that was significantly different from the other serotypes &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0125" class="elsevierStylePara elsevierViewall">Median total IgG serum levels were 7&#46;91<span class="elsevierStyleHsp" style=""></span>g&#47;L &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> and <a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; No correlation was found between IgG trough levels and pneumococcal specific antibodies for the six serotypes &#40;Pearson&#39;s correlation coefficient&#44; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>0&#46;05&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Discussion</span><p id="par0130" class="elsevierStylePara elsevierViewall">Replacement therapy with IVIG is the main treatment for PID patients who do not produce antibodies&#44; since it leads to a reduction in infection rates and prevents the most serious infections&#46;<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">2&#44;13</span></a> Hence it is crucial that intravenous immunoglobulin preparations have adequate levels of antibodies against extracellular bacteria such as <span class="elsevierStyleItalic">S&#46; pneumoniae</span>&#46;<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">10&#44;14</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">However&#44; the multiplicity of serotypes&#44; the differences in methods used to analyse the specific antibodies to <span class="elsevierStyleItalic">S&#46; pneumoniae</span>&#44; together with the criteria used for the interpretation of these antibodies<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">5</span></a> are factors that make it difficult to analyse results from such studies&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">We chose three known PID diseases in which low IgG levels and lack of antibody production are present&#46; Moreover&#44; we believe that age is not a limitation of the study as antibody production by these patients is not age-dependent&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">During the 296 clinical visits of the study period&#44; the vast majority of patients presented respiratory infections and antibiotics were prescribed in 52 situations&#46; Respiratory infections are the most frequent infections in these patients even those treated with IVIG&#46;<a class="elsevierStyleCrossRefs" href="#bib0220"><span class="elsevierStyleSup">15&#44;16</span></a> Some patients with ARI might have had viral infections&#46;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">17</span></a> However&#44; as viral episodes of infection may lead to secondary bacterial infection in patients with lung disease&#44;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">18</span></a> antibiotics were recommended in all cases&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">The recommended time interval for IVIG is 3&#8211;4 weeks and that was kept in the vast majority of our patients &#40;median&#44; 28 days&#59; range&#44; 21&#8211;34 days&#41;&#46; The interval between infusions ranged from 26 to 50 days in another study that showed a common pattern in these patients&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">19</span></a> The recommended dose for each patient was maintained during the study in accordance with other reference centres of PID<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">20</span></a> and patients with any lung disease received higher doses compared with patients without pulmonary sequels&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">Antibodies to pneumococcal serotypes 1&#44; 5&#44; 6B and 9V were present in levels below 1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL in many patients in our study&#46; Serotypes 14 and 19F are also important causes of pneumococcal invasive disease in our country&#44;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">21</span></a> but fortunately all patients presented protective antibody levels to these serotypes in all analysed samples&#46; Altogether&#44; the six pneumococcal serotypes analysed in this study represent 20&#46;6&#37; of <span class="elsevierStyleItalic">S&#46; pneumoniae</span> isolated in adults and children over five years in Brazil in 2011&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">21</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">Pneumococcal antibody levels were not lower in patients who received doses equal to or lower than 500<span class="elsevierStyleHsp" style=""></span>mg&#47;kg or in those diagnosed with XLA&#46; Patients who are receiving lower IVIG doses are those who present mild disease without lung sequel and this could be a reason for a lower intake of IVIG&#46; However&#44; other factors might interfere with IgG catabolism&#46; As reviewed by Bonilla&#44;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">22</span></a> the IgG catabolism is mediated by FcRn and higher cumulative IgG doses over time tend to be associated with a shorter half-life of IgG in serum&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">Different from previous studies&#44; the behaviour of pneumococcal antibody levels was shown in a prospective way&#46; In general&#44; it is assumed that patients on regular IVIG treatment are provided with high antibody levels against varied pathogens and are protected&#46; However&#44; our results showed that the maintenance of antibodies above 1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL during one year for all six serotypes was only observed in a minority of individuals &#40;28&#46;6&#37;&#41;&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">Another very important issue was the opportunity this study provided to evaluate different brands of IVIG in the same group of patients&#46; The analyses also show that there is a high variation of antibody concentrations in the samples studied&#46; IVIG purification methods are manufacturer specific and unique with respect to specific conditions during fractionation and the combination of methods used to decrease aggregate formation&#44; to remove proteins associated with adverse events&#44; and to provide viral clearance&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">23</span></a></p><p id="par0175" class="elsevierStylePara elsevierViewall">The administration of IVIG results in a peak concentration of total IgG that decreases over time before the next infusion&#46; The concentration of IgG in the serum immediately before the next infusion of IVIG is seen by most immunologists as an important guide to therapy<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">24</span></a> and a significant reduction in pneumonia incidence is associated with higher trough IgG levels in patients with antibody deficiency&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">25</span></a> However&#44; no correlation between total IgG levels and specific antibody levels were noted in our results&#44; suggesting that high or adequate trough IgG levels might not always ensure protective antibody levels to different pathogens&#46; Different results were observed when only one IVIG brand was used&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">19</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">It was also not possible to correlate the occurrence of respiratory infections with pneumococcal antibody levels&#46; Likewise&#44; a previous attempt to correlate pneumococcal antibody levels with acute exacerbation in patients with chronic pulmonary diseases was not successful&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">26</span></a> For PID patients these correlations are more difficult to establish&#58; even in patients with recommended IgG levels &#40;IgG &#62;7&#46;0<span class="elsevierStyleHsp" style=""></span>g&#47;L&#41;&#44; suboptimal pneumococcal antibodies were observed&#46;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">27</span></a> Also&#44; even when protective antibody levels are present in serum&#44; patients with severe impaired antibody production are not fully protected from presenting some form of disease&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">28</span></a></p><p id="par0185" class="elsevierStylePara elsevierViewall">There is a wide variation in specific antibody levels in different IVIG brands and lots to different antigens&#46;<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">10&#44;14&#44;29</span></a> The variation in this study of pneumococcal antibodies in IVIG analysed was above 30&#37; for several serotypes in the different brands and lots&#44; a little bit higher when compared to the results from Lejtenyi and Mazer&#46; However&#44; these authors analysed only one brand of IVIG&#46;<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">10</span></a> Interestingly&#44; the higher antibody concentrations found for serotype 19F in IVIG preparations were not found when the patients&#8217; serum samples were analysed&#58; in these samples&#44; antibodies to serotype 14 were usually higher than the other serotypes&#46; This might indicate that assessing specific antibodies only in IVIG preparations cannot be sufficient to predict antibody concentrations in the patients&#8217; serum&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">Therefore&#44; despite the proven efficacy of IVIG&#44; it would be interesting to monitor the causative pathogens of infections affecting these patients and the level of specific antibodies&#46; This investigation could generate important data on the behaviour of specific antibodies in these patients&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Conclusion</span><p id="par0195" class="elsevierStylePara elsevierViewall">Pneumococcal antibodies are present in a high range of concentrations in sera from PID patients and also in IVIG preparations&#46; Even maintaining a recommended IgG trough level&#44; these patients can be susceptible to these bacteria and that may contribute to recurrent respiratory infections&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Ethical disclosures</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Confidentiality of data</span><p id="par0200" class="elsevierStylePara elsevierViewall">The authors declare that they have followed the protocols of their work centre on the publication of patient data and that all the patients included in the study have received sufficient information and have given their informed consent in writing to participate in that study&#46;</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Right to privacy and informed consent</span><p id="par0205" class="elsevierStylePara elsevierViewall">The authors have obtained the informed consent of the patients mentioned in the article&#46; The author for correspondence is in possession of this document&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Protection of human subjects and animals in research</span><p id="par0210" class="elsevierStylePara elsevierViewall">The authors declare that the procedures followed were in accordance with the regulations of the responsible Clinical Research Ethics Committee and in accordance with those of the World Medical Association and the Helsinki Declaration&#46;</p></span></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Financial support</span><p id="par0215" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleGrantSponsor" id="gs1">CAPES</span>&#44; a Brazilian Funding Agency&#46;</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conflict of interest</span><p id="par0220" class="elsevierStylePara elsevierViewall">The authors declare no conflict of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres783844"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Background"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Methods"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec782732"
          "titulo" => "Keywords"
        ]
        2 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        3 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Patients and methods"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Collection of blood and IVIG samples"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Measurement of antibodies to S&#46; pneumoniae by ELISA"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Statistical analysis"
            ]
          ]
        ]
        4 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Results"
        ]
        5 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Discussion"
        ]
        6 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Conclusion"
        ]
        7 => array:3 [
          "identificador" => "sec0045"
          "titulo" => "Ethical disclosures"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Confidentiality of data"
            ]
            1 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Right to privacy and informed consent"
            ]
            2 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "Protection of human subjects and animals in research"
            ]
          ]
        ]
        8 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Financial support"
        ]
        9 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Conflict of interest"
        ]
        10 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2016-02-10"
    "fechaAceptado" => "2016-04-27"
    "PalabrasClave" => array:1 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec782732"
          "palabras" => array:6 [
            0 => "Antibody deficiency"
            1 => "Hypogammaglobinaemia"
            2 => "Intravenous immunoglobulin"
            3 => "Pneumococcal infection"
            4 => "Primary immunodeficiency disease"
            5 => "<span class="elsevierStyleItalic">Streptococcus pneumoniae</span>"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">This is a prospective study that assessed pneumococcal antibody levels in PID patients under intravenous immunoglobulin &#40;IVIG&#41; treatment using different brands&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Twenty-one patients receiving regular IVIG every 28 days were invited to participate&#58; 12 with common variable immunodeficiency&#44; six with X-linked agammaglobulinaemia and three with hyper-IgM syndrome&#46;</p><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">One blood sample was collected from each patient just prior to IVIG administration at a three-month time interval during one year&#46; A questionnaire was filled in with patient&#39;s demographic data and history of infections during the study period&#46; <span class="elsevierStyleItalic">Streptococcus pneumoniae</span> antibodies against six serotypes &#40;1&#44; 5&#44; 6B&#44; 9V&#44; 14 and 19F&#41; were assessed by ELISA both in patients&#8217; serum &#40;trough levels&#41; and in IVIG samples&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Median total IgG trough serum levels were 7&#46;91<span class="elsevierStyleHsp" style=""></span>g&#47;L &#40;range&#44; 4&#46;59&#8211;12&#46;20&#41;&#46; All patients had antibody levels above 0&#46;35<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL to the six serotypes on all four measurements&#46; However&#44; only 28&#46;6&#37; of patients had pneumococcal antibodies for the six analysed serotypes above 1&#46;3<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;mL on all four evaluations during the one-year period&#46; No correlation was found between IgG trough levels and pneumococcal specific antibodies&#46; Eighteen of the 21 patients &#40;85&#46;7&#37;&#41; had infections at some point during the 12-month follow-up&#44; 62&#47;64 &#40;96&#46;9&#37;&#41; clinically classified in respiratory tract infections&#44; four of which were pneumonia&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Pneumococcal antibodies are present in a high range of concentrations in sera from PID patients and also in IVIG preparations&#46; Even maintaining a recommended IgG trough level&#44; these patients can be susceptible to these bacteria and that may contribute to recurrent respiratory infections&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Background"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Methods"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
    ]
    "multimedia" => array:6 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1114
            "Ancho" => 1605
            "Tamanyo" => 70332
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Total IgG measured in serum samples of patients on regular use of intravenous immunoglobulin&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1455
            "Ancho" => 3345
            "Tamanyo" => 245452
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Correlation between total IgG and pneumococcal antibodies of six serotypes of pneumococcal measured in 84 serum samples of patients on regular use of intravenous immunoglobulin&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Parameter&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Values&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Median age in years &#40;range&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">20&#46;7 &#40;3&#8211;42&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Male gender &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11 &#40;52&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Number of patients using antimicrobial prophylaxis &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6 &#40;28&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Median dose of IVIG administered to patients &#40;range&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">550<span class="elsevierStyleHsp" style=""></span>mg&#47;kg &#40;340&#8211;760&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Median serum trough IgG levels in patients &#40;range&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#46;91<span class="elsevierStyleHsp" style=""></span>g&#47;L &#40;4&#46;6&#8211;12&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Median follow-up of each patient during study period in months &#40;range&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13&#46;9 &#40;11&#46;5&#8211;15&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1302785.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Demographic characteristics of study patients&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Visits to Immunology Clinic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Infectious episodes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Admission to hospital&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Pulmonary sequel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Continuous antimicrobial prophylaxis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Number of antimicrobial treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Other medication&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4 ARI&#47;1 PMN&#47;1 AOM&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Topical steroid&#47;Bronchodilator&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 sinusitis&#47;1 ARI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Corticosteroids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 pharyngitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Corticosteroids&#47;Bronchodilator&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 ARI&#47;1 cutaneous infection&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Corticosteroids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 ARI&#47;1 AOM&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Corticosteroids&#47;Bronchodilator&#47;Antidepressant&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3 ARI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Bronchodilator&#47;Corticosteroids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4 ARI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Corticosteroids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 ARI&#47;1 AOM&#47;1 sinusitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 urinary infection&#47;2 ARI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 ARI&#47;1 conjunctivitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 ARI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Antiviral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 ARI&#47;1 conjunctivitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Antihistamine drug&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4 ARI&#47;1 PMN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Bronchodilator&#47;Corticosteroids&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6 ARI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8 ARI&#47;1 PMN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 ARI&#47;1 PMN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Antiviral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3 ARI&#47;1 sinusitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="char" valign="top">21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 ARI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1302783.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Antimicrobial prophylaxis prescribed but not taken by patient&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Medical records of patients in the study period &#40;AOM&#44; acute otitis media&#59; ARI&#44; acute respiratory infection&#59; PNM&#44; pneumonia&#41;&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">na&#58; not applicable&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Pneumococcal serotype&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="5" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Proportion of samples with pneumococcal antibodies<br>&#62;1&#46;3<span class="elsevierStyleHsp" style=""></span>mcg&#47;mL</th><th class="td" title="table-head  " align="left" valign="top" scope="col">Pneumococcal antibodies in sera&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col">Pneumococcal antibodies in IGIV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">1st sample<br>&#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">2nd sample<br>&#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">3rd sample<br>&#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">4th sample<br>&#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">All 4 samples&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median and range &#40;&#956;g&#47;mL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median and range &#40;&#956;g&#47;mg IgG&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">95&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">80&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">85&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">61&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#46;8 &#40;0&#46;91&#8211;30&#46;04&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;66 &#40;0&#46;04&#8211;1&#46;34&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">85&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">76&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">71&#46;4&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#46;2 &#40;0&#46;74&#8211;31&#46;34&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;14 &#40;0&#46;01&#8211;0&#46;42&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">6B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">95&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">95&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">90&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&#46;6 &#40;0&#46;63&#8211;54&#46;90&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;24 &#40;0&#46;02&#8211;1&#46;12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">9V&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">95&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">90&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">85&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#46;7 &#40;1&#46;09&#8211;51&#46;70&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;54 &#40;0&#46;17&#8211;1&#46;37&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6&#46;7 &#40;2&#46;15&#8211;41&#46;96&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;30 &#40;0&#46;09&#8211;2&#46;08&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">19F&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&#46;8 &#40;1&#46;46&#8211;29&#46;78&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1&#46;06 &#40;0&#46;30&#8211;2&#46;19&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">All tested serotypes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">90&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">71&#46;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">57&#46;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">28&#46;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">na&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">na&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1302784.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Prospective immunological evaluation of patients on regular use of IGIV&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Brand&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 1</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 5</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 6B</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 9V</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 14</th><th class="td" title="table-head  " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Serotype 19F</th></tr><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median<br>Antibody level &#40;&#956;g&#47;mg IgG&#41;<br>&#40;Q1&#8211;Q3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median<br>Antibody level &#40;&#956;g&#47;mg IgG&#41;<br>&#40;Q1&#8211;Q3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median<br>Antibody level &#40;&#956;g&#47;mg IgG&#41;<br>&#40;Q1&#8211;Q3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median<br>Antibody level &#40;&#956;g&#47;mg IgG&#41;<br>&#40;Q1&#8211;Q3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median<br>Antibody level &#40;&#956;g&#47;mg IgG&#41;<br>&#40;Q1&#8211;Q3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Median<br>Antibody level &#40;&#956;g&#47;mg IgG&#41;<br>&#40;Q1&#8211;Q3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Octagam<span class="elsevierStyleSup">&#174;</span><br><span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;84 &#40;0&#46;77&#8211;1&#46;00&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;61&#8211;1&#46;34&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;16 &#40;0&#46;14&#8211;0&#46;23&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;11&#8211;0&#46;26&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;25 &#40;0&#46;21&#8211;0&#46;32&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;14&#8211;1&#46;12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;76 &#40;0&#46;59&#8211;0&#46;90&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;17&#8211;1&#46;37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;31 &#40;0&#46;28&#8211;0&#46;39&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;25&#8211;2&#46;07&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;37 &#40;0&#46;89&#8211;1&#46;60&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;30&#8211;2&#46;00&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Flebogamma<span class="elsevierStyleSup">&#174;</span><br><span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;34 &#40;0&#46;25&#8211;0&#46;46&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;25&#8211;0&#46;64&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;06 &#40;0&#46;05&#8211;0&#46;07&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;05&#8211;0&#46;09&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;07 &#40;0&#46;07&#8211;0&#46;08&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;06&#8211;0&#46;23&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;4 &#40;0&#46;38&#8211;0&#46;48&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;36&#8211;0&#46;59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;17 &#40;0&#46;15&#8211;0&#46;19&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;15&#8211;0&#46;43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;90 &#40;0&#46;87&#8211;1&#46;02&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;85&#8211;1&#46;69&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Endobulin<span class="elsevierStyleSup">&#174;</span><br><span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;05 &#40;0&#46;04&#8211;0&#46;07&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;04&#8211;0&#46;08&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;01 &#40;0&#46;01&#8211;0&#46;01&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;01&#8211;0&#46;02&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;03 &#40;0&#46;02&#8211;0&#46;03&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;02&#8211;0&#46;03&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;28 &#40;0&#46;25&#8211;0&#46;35&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;23&#8211;0&#46;43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;11 &#40;0&#46;10&#8211;0&#46;12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;09&#8211;0&#46;12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;55 &#40;0&#46;53&#8211;0&#46;68&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;50&#8211;0&#46;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Blausigel<span class="elsevierStyleSup">&#174;</span><br><span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;80 &#40;0&#46;77&#8211;0&#46;82&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;75&#8211;0&#46;85&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;14 &#40;0&#46;14&#8211;0&#46;15&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;14&#8211;0&#46;15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;21 &#40;0&#46;20&#8211;0&#46;23&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;18&#8211;0&#46;24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;98 &#40;0&#46;93&#8211;1&#46;03&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;90&#8211;1&#46;08&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;21 &#40;0&#46;18&#8211;0&#46;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;15&#8211;0&#46;28&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;69 &#40;1&#46;44&#8211;1&#46;94&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;19&#8211;2&#46;19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tegeline<span class="elsevierStyleSup">&#174;</span><br><span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;36 &#40;0&#46;24&#8211;0&#46;57&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;13&#8211;0&#46;99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;01 &#40;0&#46;07&#8211;0&#46;27&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;03&#8211;0&#46;42&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;57 &#40;0&#46;34&#8211;0&#46;79&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;05&#8211;1&#46;12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;41 &#40;0&#46;29&#8211;0&#46;45&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;21&#8211;1&#46;16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;60 &#40;0&#46;52&#8211;0&#46;89&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;10&#8211;1&#46;30&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;90 &#40;0&#46;71&#8211;1&#46;24&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;37&#8211;1&#46;55&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Vigam<span class="elsevierStyleSup">&#174;</span><br><span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;88 &#40;0&#46;78&#8211;0&#46;97&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;69&#8211;1&#46;07&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;14 &#40;0&#46;10&#8211;0&#46;18&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;05&#8211;0&#46;23&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;83 &#40;0&#46;77&#8211;0&#46;89&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;70&#8211;0&#46;95&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;70 &#40;0&#46;61&#8211;0&#46;80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;52&#8211;0&#46;89&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;99 &#40;0&#46;75&#8211;1&#46;23&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;50&#8211;1&#46;47&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;52 &#40;1&#46;36&#8211;1&#46;69&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&#46;19&#8211;1&#46;85&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="13" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Coefficient of variation &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " colspan="2" align="center" valign="top">54&#46;86&#37;</td><td class="td" title="table-entry  " colspan="2" align="center" valign="top">66&#46;70&#37;</td><td class="td" title="table-entry  " colspan="2" align="center" valign="top">93&#46;28&#37;</td><td class="td" title="table-entry  " colspan="2" align="center" valign="top">52&#46;01&#37;</td><td class="td" title="table-entry  " colspan="2" align="center" valign="top">93&#46;60&#37;</td><td class="td" title="table-entry  " colspan="2" align="center" valign="top">42&#46;98&#37;</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1302786.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Pneumococcal antibodies in different lots of commercially available preparations of intravenous immunoglobulin used in study&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:29 [
            0 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pathogenesis&#44; diagnosis&#44; and management of primary antibody deficiencies and infections"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;J&#46; Fried"
                            1 => "F&#46;A&#46; Bonilla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1128/CMR.00001-09"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Microbiol Rev"
                        "fecha" => "2009"
                        "volumen" => "22"
                        "paginaInicial" => "396"
                        "paginaFinal" => "414"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19597006"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "P&#46;J&#46; Busse"
                            1 => "S&#46; Razvi"
                            2 => "C&#46; Cunningham-Rundles"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol"
                        "fecha" => "2002"
                        "volumen" => "109"
                        "paginaInicial" => "1001"
                        "paginaFinal" => "1004"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12063531"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infections in 252 patients with common variable immunodeficiency"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Oksenhendler"
                            1 => "L&#46; G&#233;rard"
                            2 => "C&#46; Fieschi"
                            3 => "M&#46; Malphettes"
                            4 => "G&#46; Mouillot"
                            5 => "R&#46; Jaussaud"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1086/587669"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Infect Dis"
                        "fecha" => "2008"
                        "volumen" => "46"
                        "paginaInicial" => "1547"
                        "paginaFinal" => "1554"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18419489"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;R&#46; Siber"
                            1 => "I&#46; Chang"
                            2 => "S&#46; Baker"
                            3 => "P&#46; Fernsten"
                            4 => "K&#46;L&#46; O&#8217;Brien"
                            5 => "M&#46; Santosham"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.vaccine.2007.01.119"
                      "Revista" => array:6 [
                        "tituloSerie" => "Vaccine"
                        "fecha" => "2007"
                        "volumen" => "25"
                        "paginaInicial" => "3816"
                        "paginaFinal" => "3826"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17368878"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Post-immunization pneumococcal antibody titers and IgG subclasses"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "R&#46;U&#46; Sorensen"
                            1 => "H&#46; Hidalgo"
                            2 => "C&#46; Moore"
                            3 => "L&#46;E&#46; Leiva"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/(SICI)1099-0496(199609)22:3<167::AID-PPUL5>3.0.CO;2-M"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pediatr Pulmonol"
                        "fecha" => "1996"
                        "volumen" => "22"
                        "paginaInicial" => "167"
                        "paginaFinal" => "173"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8893255"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The immunological basis for immunization series&#58; module 12&#58; pneumococcal vaccines"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "H&#46; K&#228;yhty"
                            1 => "A&#46; Nurkka"
                            2 => "A&#46; Soininen"
                            3 => "M&#46; V&#228;kev&#228;inen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Immun Vaccines Biol"
                        "fecha" => "2009"
                        "volumen" => "12"
                        "paginaInicial" => "1"
                        "paginaFinal" => "61"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies &#40;XLA&#44; HIM&#44; CVID&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "B&#46; Bayrakci"
                            1 => "F&#46; Ersoy"
                            2 => "O&#46; Sanal"
                            3 => "S&#46; Kilic"
                            4 => "A&#46; Metin"
                            5 => "I&#46; Tezcan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Turk J Pediatr"
                        "fecha" => "2005"
                        "volumen" => "47"
                        "paginaInicial" => "239"
                        "paginaFinal" => "246"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16250308"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Use of intravenous immunoglobulin in human disease&#58; a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "J&#46;S&#46; Orange"
                            1 => "E&#46;M&#46; Hossny"
                            2 => "C&#46;R&#46; Weiler"
                            3 => "M&#46; Ballow"
                            4 => "M&#46; Berger"
                            5 => "F&#46;A&#46; Bonilla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Allergy Clin Immunol"
                        "fecha" => "2006"
                        "volumen" => "117"
                        "paginaInicial" => "525"
                        "paginaFinal" => "553"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "IgG antibody reactive with five serotypes of <span class="elsevierStyleItalic">Streptococcus pneumoniae</span> in commercial intravenous immunoglobulin preparations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46;J&#46; Hamill"
                            1 => "D&#46;M&#46; Musher"
                            2 => "J&#46;E&#46; Groover"
                            3 => "P&#46;J&#46; Zavell"
                            4 => "D&#46;A&#46; Watson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Infect Dis"
                        "fecha" => "1991"
                        "volumen" => "166"
                        "paginaInicial" => "38"
                        "paginaFinal" => "42"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1607706"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "D&#46; Lejtenyi"
                            1 => "B&#46; Mazer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaci.2007.11.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol"
                        "fecha" => "2008"
                        "volumen" => "121"
                        "paginaInicial" => "254"
                        "paginaFinal" => "255"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18206511"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "<span class="elsevierStyleItalic">Streptococcus pneumoniae</span> antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin &#40;IVIG&#41; compared to subcutaneous immunoglobulin &#40;SCIG&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46;P&#46; Knutsen"
                            1 => "L&#46;E&#46; Leiva"
                            2 => "C&#46; Caruthers"
                            3 => "J&#46; Rodrigues"
                            4 => "R&#46;U&#46; Sorensen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cei.12665"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Immunol"
                        "fecha" => "2015"
                        "volumen" => "182"
                        "paginaInicial" => "51"
                        "paginaFinal" => "56"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26230522"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Quantitation of antibodies in the sera of immunodeficient patients receiving monthly intravenous immune globulin &#40;IVIg&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46;M&#46; Pieretti"
                            1 => "C&#46; Cunningham-Rundles"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "J Allergy Clin Immunol"
                        "fecha" => "2009"
                        "volumen" => "123"
                        "paginaInicial" => "S14"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia&#58; a retrospective survey of 31 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Quartier"
                            1 => "M&#46; Debr&#233;"
                            2 => "J&#46; De Blic"
                            3 => "R&#46; de Sauverzac"
                            4 => "N&#46; Sayegh"
                            5 => "N&#46; Jabado"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Pediatr"
                        "fecha" => "1999"
                        "volumen" => "134"
                        "paginaInicial" => "589"
                        "paginaFinal" => "596"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10228295"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Characterization of antibodies to capsular polysaccharide antigens of <span class="elsevierStyleItalic">Haemophilus influenzae</span> type b and <span class="elsevierStyleItalic">Streptococcus pneumoniae</span> in human immune globulin intravenous preparations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;G&#46; Mikolajczyk"
                            1 => "N&#46;F&#46; Concepcion"
                            2 => "T&#46; Wang"
                            3 => "D&#46; Frazier"
                            4 => "B&#46; Golding"
                            5 => "C&#46;E&#46; Frasch"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1128/CDLI.11.6.1158-1164.2004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Diagn Lab Immunol"
                        "fecha" => "2004"
                        "volumen" => "11"
                        "paginaInicial" => "1158"
                        "paginaFinal" => "1164"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15539522"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Survey of infection in patients receiving antibody replacement treatment for immune deficiency"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46;J&#46; Pettit"
                            1 => "H&#46; Bourne"
                            2 => "G&#46;P&#46; Spickett"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Pathol"
                        "fecha" => "2002"
                        "volumen" => "55"
                        "paginaInicial" => "577"
                        "paginaFinal" => "580"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12147649"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infections in 252 patients with common variable immunodeficiency"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "DEFI Study Group"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Oksenhendler"
                            1 => "L&#46; G&#233;rard"
                            2 => "C&#46; Fieschi"
                            3 => "M&#46; Malphettes"
                            4 => "G&#46; Mouillot"
                            5 => "R&#46; Jaussaud"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1086/587669"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Infect Dis"
                        "fecha" => "2008"
                        "volumen" => "46"
                        "paginaInicial" => "1547"
                        "paginaFinal" => "1554"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18419489"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Frequency and clinical outcome of respiratory viral infections and mixed viral-bacterial infections in children with cancer&#44; fever and neutropenia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;P&#46; Torres"
                            1 => "Y&#46; Labra&#241;a"
                            2 => "C&#46; Iba&#241;ez"
                            3 => "P&#46; Kasaneva"
                            4 => "M&#46;J&#46; Farf&#225;n"
                            5 => "V&#46; De la Maza"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/INF.0b013e31825c4b7e"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pediatr Infect Dis J"
                        "fecha" => "2012"
                        "volumen" => "31"
                        "paginaInicial" => "889"
                        "paginaFinal" => "893"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22565292"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infection as a comorbidity of COPD"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "S&#46; Sethi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1183/09031936.00081409"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Respir J"
                        "fecha" => "2010"
                        "volumen" => "35"
                        "paginaInicial" => "1209"
                        "paginaFinal" => "1215"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20513910"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pneumococcal antibody levels in children with PID receiving immunoglobulin"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Tuerlinckx"
                            1 => "B&#46; Florkin"
                            2 => "A&#46; Ferster"
                            3 => "I&#46; De Schutter"
                            4 => "C&#46; Chantrain"
                            5 => "F&#46; Haerynck"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1542/peds.2013-1155"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pediatrics"
                        "fecha" => "2014"
                        "volumen" => "133"
                        "paginaInicial" => "e154"
                        "paginaFinal" => "e162"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24366995"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical picture and treatment of 2212 patients with common variable immunodeficiency"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "European Society for Immunodeficiencies Registry Working Party"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Gathmann"
                            1 => "N&#46; Mahlaoui"
                            2 => "L&#46; G&#233;rard"
                            3 => "E&#46; Oksenhendler"
                            4 => "K&#46; Warnatz"
                            5 => "I&#46; Schulze"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaci.2013.12.1077"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol"
                        "fecha" => "2014"
                        "volumen" => "134"
                        "paginaInicial" => "116"
                        "paginaFinal" => "126"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24582312"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "378 pp&#46;"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Informe Regional de SIREVA II&#44; 2011&#58; datos por pa&#237;s y por grupos de edad sobre las caracter&#237;sticas de los aislamientos de <span class="elsevierStyleItalic">Streptococcus pneumoniae</span>&#44; <span class="elsevierStyleItalic">Haemophilus influenzae</span> y <span class="elsevierStyleItalic">Neisseria meningitidis</span> en procesos invasores"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Organizaci&#243;n Panamericana de la Salud"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "2012"
                        "editorial" => "OPAS"
                        "editorialLocalizacion" => "Washington&#44; DC"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "F&#46;A&#46; Bonilla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.iac.2008.06.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Immunol Allergy Clin North Am"
                        "fecha" => "2008"
                        "volumen" => "28"
                        "paginaInicial" => "803"
                        "paginaFinal" => "819"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18940575"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intravenous immune globulins&#58; therapeutic&#44; pharmaceutical&#44; &#38; cost considerations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "J&#46; Siegel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Pharm Pract"
                        "fecha" => "2001"
                        "volumen" => "28"
                        "paginaInicial" => "11"
                        "paginaFinal" => "13"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies&#58; a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46;L&#46; Yong"
                            1 => "J&#46; Boyle"
                            2 => "M&#46; Ballow"
                            3 => "M&#46; Boyle"
                            4 => "M&#46; Berger"
                            5 => "J&#46; Bleesing"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clim.2009.10.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Immunol"
                        "fecha" => "2010"
                        "volumen" => "135"
                        "paginaInicial" => "255"
                        "paginaFinal" => "263"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19914873"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impact of trough IgG on pneumonia incidence in primary immunodeficiency&#58; a meta-analysis of clinical studies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46;S&#46; Orange"
                            1 => "W&#46;J&#46; Grossman"
                            2 => "R&#46;J&#46; Navickis"
                            3 => "M&#46;M&#46; Wilkes"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clim.2010.06.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Immunol"
                        "fecha" => "2010"
                        "volumen" => "137"
                        "paginaInicial" => "21"
                        "paginaFinal" => "30"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20675197"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;T&#46; Yerkovich"
                            1 => "B&#46;J&#46; Hales"
                            2 => "M&#46;L&#46; Carroll"
                            3 => "J&#46;G&#46; Burel"
                            4 => "M&#46;A&#46; Towers"
                            5 => "D&#46;J&#46; Smith"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-2466-12-37"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Pulm Med"
                        "fecha" => "2012"
                        "volumen" => "12"
                        "paginaInicial" => "37"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22849333"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pathogen-specific IgG antibody levels in patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "I&#46; Chua"
                            1 => "M&#46; Lagos"
                            2 => "B&#46;M&#46; Cjarambolous"
                            3 => "S&#46; Workman"
                            4 => "R&#46; Chee"
                            5 => "B&#46; Grimbacher"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaci.2011.01.035"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol"
                        "fecha" => "2011"
                        "volumen" => "127"
                        "paginaInicial" => "1410"
                        "paginaFinal" => "1411"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21376379"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Protective levels of Varicella-Zoster antibody did not effectively prevent chickenpox in an X-linked agammaglobulinemia patient"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "F&#46;A&#46; Nobre"
                            1 => "I&#46;G&#46; Gonzalez"
                            2 => "M&#46;I&#46; Moraes-Pinto"
                            3 => "B&#46;T&#46; Costa-Carvalho"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1590/S0036-46652015000500017"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Inst Med Trop Sao Paulo"
                        "fecha" => "2015"
                        "volumen" => "57"
                        "paginaInicial" => "455"
                        "paginaFinal" => "457"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26603238"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Antibody levels to tetanus&#44; diphtheria&#44; measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy&#58; a prospective study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "F&#46;A&#46; Nobre"
                            1 => "I&#46;G&#46; Gonzalez"
                            2 => "R&#46;M&#46; Sim&#227;o"
                            3 => "M&#46;I&#46; de Moraes-Pinto"
                            4 => "B&#46;T&#46; Costa-Carvalho"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-2172-15-26"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Immunol"
                        "fecha" => "2014"
                        "volumen" => "15"
                        "paginaInicial" => "26"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24952415"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/03010546/0000004500000001/v1_201612300037/S0301054616300763/v1_201612300037/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "5554"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original articles"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/03010546/0000004500000001/v1_201612300037/S0301054616300763/v1_201612300037/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0301054616300763?idApp=UINPBA00004N"
]

Article information

ISSN: 03010546
Original language: English

DOI:10.1016/j.aller.2016.04.014

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	3	0	3
2024 October	24	2	26
2024 September	33	2	35
2024 August	39	4	43
2024 July	20	1	21
2024 June	33	2	35
2024 May	27	3	30
2024 April	22	1	23
2024 March	26	11	37
2024 February	23	3	26
2024 January	33	8	41
2023 December	27	7	34
2023 November	18	9	27
2023 October	36	14	50
2023 September	28	1	29
2023 August	39	8	47
2023 July	31	2	33
2023 June	26	3	29
2023 May	71	0	71
2023 April	55	1	56
2023 March	24	2	26
2023 February	14	11	25
2023 January	20	8	28
2022 December	17	6	23
2022 November	20	5	25
2022 October	15	8	23
2022 September	15	6	21
2022 August	22	8	30
2022 July	24	8	32
2022 June	17	4	21
2022 May	18	6	24
2022 April	23	12	35
2022 March	25	8	33
2022 February	40	6	46
2022 January	60	5	65
2021 December	37	10	47
2021 November	17	11	28
2021 October	37	11	48
2021 September	41	9	50
2021 August	22	8	30
2021 July	10	10	20
2021 June	16	9	25
2021 May	17	9	26
2021 April	36	17	53
2021 March	28	10	38
2021 February	32	10	42
2021 January	29	10	39
2020 October	1	0	1
2020 July	0	1	1
2018 February	2	2	4
2018 January	6	3	9
2017 December	0	3	3
2017 November	0	2	2
2017 February	1	0	1
2017 January	2	0	2
2016 October	0	1	1

Show all

Allergologia et Immunopathologia is no longer published on Elsevier since the 2021 year.Transferred to Codon Publications

Indexed in:

Follow us:

Statistics

Allergologia et Immunopathologia is no longer published on Elsevier since the 2021 year.Transferred to Codon Publications

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter